Table of ContentsTable of Contents............................................................................................................. 1
Study 331-201-[ZIP_CODE] Protocol Amendment 5; 07 Jul 2022............................................ 2
Study 331-201-[ZIP_CODE] Protocol Addendum; 06 Jul 2020................................................. 96Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
1
Otsuka Pharmaceutical 
Development & Commercialization, Inc.
Investigational Medicinal Product
Brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE])
REVISED CLINICAL PROTOCOL
Protocol 331-201-[ZIP_CODE]: A Phase 3, Multicenter, Open-label Trial to Evaluate the 
Long-term Safety and Tolerability of Brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE]) in the Treatment of 
Children and Adolescents with Irritability Associated with Autism Spectrum Disorder
Protocol No. 331-201-[ADDRESS_1146116] No. 2018-004899-35 
CONFIDENTIAL â€“ PROPRIETARY INFORMATION
Clinical Development Phase: 3Sponsor: Otsuka Pharmaceutical Development &
Commercialization, Inc.2440 Research BoulevardRockville, Maryland [ZIP_CODE], [LOCATION_002]
Immediately Reportable Event [EMAIL_15722]
  
Issue Date: 02 May 2019 
Version No.: 6.0&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331-201-[ADDRESS_1146117] safety and maintain protocol requirements.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
3
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 3 Version 6.0, 07 Jul 2022Protocol Synopsis 
Name [CONTACT_790]: Otsuka Pharmaceutical 
Development & Commercialization, Inc.
Name [CONTACT_92732]:  
Brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE])Protocol No.: 331-201-[ZIP_CODE]
IND No.: [ADDRESS_1146118] No.: 
2018-004899-35
Protocol Title: Protocol 331-201-[ZIP_CODE]: A Phase 3, Multicenter, Open-label 
Trial to Evaluate the Long-term Safety and Tolerability of 
Brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE]) in the Treatment of Children and 
Adolescents with Irritability Associated with Autism Spectrum 
Disorder
Clinical Phase/Trial 
Type:3/Safety extension
Treatment Indication: Irritability associated with autism spectrum disorder (ASD)
Objective(s): Primary: To assess the long-term safety and tolerability of 
brexpi[INVESTIGATOR_826286].
Secondary: To assess the long-term efficacy of brexpi[INVESTIGATOR_826287].
Trial Design: This is a phase 3, multicenter, open-label trial designed to 
assess the long-term safety and tolerability of oral 
brexpi[INVESTIGATOR_826288]. The trial is planned to be conducted on an 
outpatient basis. Enrollment into the trial will be drawn from 
eligible subjects who completed the treatment period in the 
double-blind, phase 3 efficacy trial (331-201-[ZIP_CODE] [8 weeks 
of treatment]) and, in the investigatorâ€™s judgment, could 
potentially benefit from continued investigational treatment 
with oral brexpi[INVESTIGATOR_4253]. 
The trial will be conducted as follows:
Screening/Baseline: Subjects who completed the treatment 
period of the double-blind trial and were deemed compliant 
with the protocol will be screened for eligibility at the last visit 
of the double-blind trial (Week 8). A separate fully executed 
informed consent/assent will be obtained for 
Trial 331-201-[ADDRESS_1146119] 
visit of the double-blind trial will serve as the baseline 
measures for Trial 331-201-[ZIP_CODE] for any assessment that is Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
4
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 4 Version 6.0, 07 Jul 2022not unique to the open-label trial. Medical history will be 
updated, if necessary.
Open-label Treatment Phase: Eligible subjects from 
Trial 331-201-[ADDRESS_1146120] with trial personnel using online 
communication tools which incorporate telemedicine. During 
virtual interactions (and at any other time), the trial personnel 
will be able to assess the subject and determine if an additional 
in-office visit for a physical evaluation is required at the 
discretion of the investigator.
Subjects from Trial 331-201-[ZIP_CODE] will follow the 
titration/dosing schedule in the table below. Dose titrations 
will be performed in conjunction with a trial visit and 
therefore, trial visit windows are allowed for the titration 
schedule. As in the parent trial, the titration/dosing schedule 
will be based on body weight. Body weight at the Week 8 
double-blind visit/baseline visit for Trial 331-201-[ADDRESS_1146121] at this time will determine dose requirements 
throughout the trial. Those subjects with body weight < 50 kg 
will receive a target dose range of 1 to 1.5 mg, and those 
subjects with body weight â‰¥ 50 kg will receive a target dose 
range of 1.5 to 3 mg. 
Open-label Titration/Dosing Schedule for Subjects with 
Irritability Associated with ASD
Trial Day Number of 
Days on IMPBrexpi[INVESTIGATOR_826289]
(Body Weight)
< 50 kg â‰¥ 50 kg
Days 1 to 3 3 0.25 mg QD 0.5 mg QD
Days 4 to 7 4 0.5 mg QD 1.5 mg QD
Days 8 to 14 7 1 mg QD 2 mg QD
Starting at Day 
15 (earliest 
opportunity to 
increase to 
maximum dose Based on 
investigator 
discretion to 
change dose 
based on 1 or 1.5 mg QD 1.5, 2, or 3 mg 
QDClinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
5
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 5 Version 6.0, 07 Jul 2022within t
arget 
dose range)therapeutic 
effect
 or 
tolerability
IMP = investigational medicinal product; QD = once daily
Follow-up: Subjects will have follow-up contact 21 (Â± 2) days 
after the last dose of open-label brexpi[INVESTIGATOR_826290] (AEs).
This trial will be monitored by [CONTACT_120578] (DMC). The DMC will monitor safety 
based on a predetermined schedule as outlined in the DMC 
charter.
Subject Population: The trial population will include children and adolescent 
rollover subjects from the double-blind, phase 3 efficacy trial 
of brexpi[INVESTIGATOR_123107]: Trial 331-201-[ZIP_CODE] 
(irritability in ASD). 
Subjects with a Diagnostic and Statistical Manual of Mental 
Disorders, 5th edition (DSM-5) diagnosis of ASD who have 
completed Trial 331-201-[ZIP_CODE] may be enrolled into this 
open-label trial. All subjects are required to meet enrollment 
criteria for Trial 331-201-[ZIP_CODE] prior to entering the trial.
Inclusion/Exclusion 
Criteria: Key Inclusion Criteria:
â€¢Subjects who, in the opi[INVESTIGATOR_871], could 
potentially benefit from administration of oral 
brexpi[INVESTIGATOR_826291] 331-201-[ZIP_CODE].
Key Exclusion Criteria:
â€¢Subjects with a substantial protocol violation during the 
course of their participation in the double-blind phase 3 
trial (331-201-[ZIP_CODE]).  
Trial Site(s): The trial is expected to enroll subjects at approximately 
[ADDRESS_1146122](s), 
Dose, Dosage 
regimen, Treatment Brexpi[INVESTIGATOR_826292]-label 
tablets in child-resistant blister cards, each containing 
sufficient tablets for 7 (+ 2) days. All doses of brexpi[INVESTIGATOR_826293] 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
6
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 6 Version 6.0, 07 Jul 2022period, Formulation, 
Mode of Administration:will be taken orally once daily, preferably in the morning, and 
will be administered without regard to meals. Brexpi[INVESTIGATOR_826294].
Trial Assessments:
Safety:  adverse events (AEs) and concomitant medications, 
clinical laboratory tests, urinalysis, vital signs, electrocardiogram (ECG), physical examination, body weight, height, body mass index (BMI), waist circumference, extrapyramidal scales (Simpson-Angus Scale [SAS], Abnormal Involuntary Movement Scale [AIMS], and Barnes Akathisia Rating Scale [BARS]), and suicidality using the Columbia-Suicide Severity Rating Scale (C-SSRS).
Efficacy:
 Aberrant Behavior Checklist - Irritability (ABC-I) 
and subscales, Clinical Global Impression - Severity (CGI-S) scale for irritability,  
Criteria for 
Evaluation:Primary Endpoint:  Safety will be assessed by [CONTACT_826356]:
â€¢The frequency and severity of AEs, serious AEs, and 
discontinuation from the trial due to AEs.
â€¢Change from baseline to postbaseline time points in 
1) vital sign measurements, 2) electrocardiogram parameters, 3) clinical laboratory tests (including prolactin) and urinalysis, and 4) physical examination findings.
â€¢Analysis of potential suicide events recorded on the 
C-SSRS. 
â€¢Changes from baseline to postbaseline time points in 
results from extrapyramidal symptom (EPS) scales (SAS, AIMS, and BARS).
â€¢Percentage of subjects with clinically significant changes 
in weight (gain or loss) from baseline to specified time points.
â€¢Time to discontinuation.
Secondary Endpoint(s):  
â€¢Change from baseline to Week 26 in the ABC-I subscale 
score.
â€¢Change from baseline to Week 26 in CGI-S scale score 
focusing on irritability.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 7 Version 6.0, 07 Jul 2022Statistical Methods: The sample size is not based on statistical considerations, but 
rather on the number of subjects rolling over from the parent trial (Trial 331-201-[ZIP_CODE]). The trial population will be derived from eligible subjects who completed the parent trial. The sample size of this open-label trial will be limited by [CONTACT_826357].  
Descriptive statistics will be provided for all efficacy and 
safety variables. No inferential statistical analyses are planned for this open-label trial.  
Trial Duration: The duration of this trial from first subject enrolled to last 
subject completed is estimated to be approximately 36 months. Individual participation for rollover subjects who complete the trial without early withdrawal will be approximately 29 weeks, consisting of a 26-week open-label treatment period, and a 21 (Â± 2)-day follow-up. &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331-201-[ADDRESS_1146123] of Abbreviations and Definitions of Terms .......................................16
1 Introduction ........................................................................................18
1.1 Nonclinical Data................................................................................................19
1.2 Clinical Data......................................................................................................19
1.2.4 Autism Spectrum Disorder .............................................................................21
1.3 Known and Potential Risks and Benefits ..........................................................21
2 Trial Rationale and Objectives .........................................................23
2.1 Trial Rationale...................................................................................................23
2.2 Dosing Rationale ...............................................................................................23
2.3 Trial Objectives .................................................................................................25
3 Trial Design.........................................................................................25
3.1 Type/Design of Trial .........................................................................................[ADDRESS_1146124] Selection and Numbering ..................................................................30
3.4 Eligibility Criteria .............................................................................................30
3.4.1 Informed Consent/Assent ...............................................................................30
3.4.2 Inclusion Criteria ............................................................................................32
3.4.3 Exclusion Criteria ...........................................................................................32
3.5 Endpoints...........................................................................................................33
3.5.1 Primary Endpoint............................................................................................33
3.5.2 Secondary Endpoints ......................................................................................33Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
9
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 9 Version 6.0, 07 Jul [ZIP_CODE].6 Measures to Minimize/Avoid Bias....................................................................34
3.7 Trial Procedures ................................................................................................343.7.1 Schedule of Assessments................................................................................[IP_ADDRESS] Screening and Baseline ...............................................................................[IP_ADDRESS] Weeks 1, 2, 3, 4, 8, 14, 18, and 22 ..............................................................[IP_ADDRESS] End of Treatment (Week 26 or Early Termination)....................................[IP_ADDRESS] Follow-up ....................................................................................................403.7.2 Efficacy Assessments .....................................................................................[IP_ADDRESS] Aberrant Behavior Checklist.......................................................................[IP_ADDRESS] Clinical Global Impression - Severity of Illness Scale ...............................40
3.7.3 Safety Assessments.........................................................................................42
[IP_ADDRESS] Adverse Events ...........................................................................................[IP_ADDRESS] Clinical Laboratory Assessments................................................................[IP_ADDRESS] Physical Examination and Vital Signs ........................................................[IP_ADDRESS].1 Physical Examination ..............................................................................[IP_ADDRESS].2 Vital Signs ...............................................................................................[IP_ADDRESS] Electrocardiogram Assessments .................................................................[IP_ADDRESS] Other Safety Assessments...........................................................................[IP_ADDRESS].1 Simpson Angus Scale..............................................................................[IP_ADDRESS].2 Abnormal Involuntary Movement Scale .................................................[IP_ADDRESS].3 Barnes Akathisia Rating Scale ................................................................[IP_ADDRESS].4 Columbia-Suicide Severity Rating Scale ................................................483.7.4 Prior and Concomitant Medications ...............................................................493.7.5 Pharmacokinetic/Pharmacodynamic Assessments .........................................[IP_ADDRESS] Pharmacokinetic Assessments ....................................................................493.7.6 End of Trial.....................................................................................................493.7.7 Independent Data Monitoring Committee......................................................493.8 Stoppi[INVESTIGATOR_1869], Withdrawal Criteria, and Procedures......................................493.8.1 Entire Trial......................................................................................................49&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
3.6M easures to Minimiz e/Avoid Bias.................................................................... 34
3.7 Trial Procedures ................................................................................................3 4
3.7.1 Schedule of Assessments................................................................................38
[IP_ADDRESS] Screening and Baseline ...............................................................................38
[IP_ADDRESS] Weeks 1 , 2, 3, 4, 8, 14, 18, and 22 ..............................................................3 9
[IP_ADDRESS] End of Treatment (Week 26 or Early Termination)....................................3 9
[IP_ADDRESS] Follow-up ....................................................................................................4 0
3.7.2 Efficacy Assessments .....................................................................................4 0
[IP_ADDRESS] Aberrant Behavior Checklist.......................................................................4 0
[IP_ADDRESS] Clinical Global Impression - Severity of Illness Scale ...............................4 0
3.7.3 Sa fety Assessments.........................................................................................4 2
[IP_ADDRESS] Adverse Events ...........................................................................................4 2
[IP_ADDRESS] Clinical Laboratory Assessments................................................................4 2
[IP_ADDRESS] Physical Examination and Vital Signs ........................................................4 4
[IP_ADDRESS].1 Physical Examination ..............................................................................4 4
[IP_ADDRESS].2 Vital Signs ...............................................................................................4 5
[IP_ADDRESS] Electrocardiogram Assessments .................................................................4 6
[IP_ADDRESS] Other Safety Assessments...........................................................................4 7
[IP_ADDRESS].1 Simpson Angus Scale..............................................................................4 7
[IP_ADDRESS].2 Abnormal Involuntary Movement Scale .................................................4 7
[IP_ADDRESS].3 Barnes Akathisia Rating Scale ................................................................48
[IP_ADDRESS].4 Columbia-Suicide Severity Rating Scale ................................................48
3.7.4 Prior and Concomitant Medications ...............................................................4 9
3.7.5 Pharmacokinetic/Pharmacodynamic Assessments .........................................4 9
[IP_ADDRESS] Pharmacokinetic Assessments ....................................................................[ADDRESS_1146125] Discontinuation ................................................................50
[IP_ADDRESS] Treatment Interruption ................................................................................50
[IP_ADDRESS] Treatment Discontinuation..........................................................................50
[IP_ADDRESS] Documenting Reasons for Treatment Discontinuation...............................50
[IP_ADDRESS] Withdrawal of Consent ...............................................................................51
[IP_ADDRESS] Procedures to Encourage Continued Trial Participation.............................[ADDRESS_1146126] ..................................................................................63
6 Pharmacokinetic/Pharmacodynamic Analysis................................63
7 Statistical Analysis..............................................................................63
7.1 Sample Size .......................................................................................................63
7.2 Datasets for Analysis.........................................................................................63Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
11
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 11 Version 6.0, 07 Jul [ZIP_CODE].3 Handling of Missing Data .................................................................................64
7.4 Primary and Secondary Endpoint Analyses ......................................................647.4.1 Primary Endpoint Analysis.............................................................................647.4.2 Secondary Endpoint Analysis.........................................................................64
7.4.4 Interim Analysis..............................................................................................65
7.5 Analysis of Demographic and Baseline Characteristics....................................657.6 Safety Analysis..................................................................................................657.6.1 Adverse Events ...............................................................................................657.6.2 Clinical Laboratory Data ................................................................................657.6.3 Physical Examination and Vital Signs Data ...................................................657.6.4 Electrocardiogram Data..................................................................................667.6.5 Other Safety Data ...........................................................................................[IP_ADDRESS] Extrapyramidal Symptoms..........................................................................[IP_ADDRESS] Suicidality ...................................................................................................[ADDRESS_1146127] Quality Complaints.....................................688.5.2 Information Required for Reporting Purposes ...............................................688.5.3 Return Process ................................................................................................688.5.4 Assessment/Evaluation...................................................................................69
9 Records Management ........................................................................69
9.1 Source Documents.............................................................................................699.2 Data Collection..................................................................................................699.3 File Management at the Trial Site .....................................................................709.4 Records Retention at the Trial Site....................................................................70
10 Quality Control and Quality Assurance...........................................71&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
7.3 Handling of Missing Data .................................................................................6 4
7.4 Primary and Secondary Endpoint Analyses ......................................................6 4
7.4.1 Primary Endpoint Analysis.............................................................................6 4
7.4.2 Secondary Endpoint Analysis.........................................................................6 4
7.4.4 Interim Analysis..............................................................................................6 5
7.5 Analysis of Demographic and Baseline Characteristics....................................6 5
7.6 Safety Analysis..................................................................................................6 5
7.6.1 Adverse Events ...............................................................................................6 5
7.6.2 Clinical Laboratory Data ................................................................................6 5
7.6.3 Physical Examination and Vital Signs Data ...................................................6 5
7.6.4 Electrocardiogram Data..................................................................................6 6
7.6.5 Other Safety Data ...........................................................................................6 6
[IP_ADDRESS] Extrapyramidal Symptoms..........................................................................6 6
[IP_ADDRESS] Suicidality ...................................................................................................[ADDRESS_1146128] Quality Complaints.....................................68
8.5.2 Information Required for Reporting Purposes ...............................................68
8.5.3R eturn Pr ocess ................................................................................................ 68
8.5.4 Assessment/Evaluation...................................................................................[ADDRESS_1146129] of In-text Tables
Table 3.2-1 Open-label Titration/Dosing Schedule for Subjects with 
Irritability Associated with ASDa..................................................28
Table 3.4.2-1 Inclusion Criteria ...........................................................................32
Table 3.4.3-1 Exclusion Criteria ..........................................................................32
Table 3.7-1 Schedule of Assessments - Rollover Subjects from 
Trial 331-201-[ZIP_CODE] ......................................................................35
Table [IP_ADDRESS]-[ADDRESS_1146130] of Appendices
Appendix 1 Criteria for Identifying Vital Signs Outside of Normal Values 
and of Potential Clinical Relevancea..............................................77
Appendix 2 Criteria for Identifying Laboratory Values of Potential 
Clinical Relevance .........................................................................78
Appendix 3 Criteria for Identifying ECG Measurements of Potential 
Clinical Relevance .........................................................................80
Appendix 4 Protocol Amendment(s)/Administrative Change(s) ......................81Clinical Study Report 331-201-[ADDRESS_1146131] of Abbreviations and Definitions of Terms
Abbreviation Definition
AAD Agitation associated with dementia of the Alzheimerâ€™s type
ABC Aberrant Behavior Checklist
ABC-I Aberrant Behavior Checklist - Irritability
ACTH Adrenocorticotropic hormone
ADHD Attention-deficit hyperactivity disorder
AE Adverse event
AIMS Abnormal Involuntary Movement Scale
ALT Alanine aminotransferase
aPTT Activated partial thromboplastin time
ASD Autism spectrum disorder
AST Aspartate aminotransferase
AUC 0-24hArea under the plasma concentration-time curve from time [ADDRESS_1146132] observable 
concentration
BARS Barnes Akathisia Rating Scale
BMI Body mass index
BUN Blood urea nitrogen
CGI-S Clinical Global Impression - Severity
CL/F Apparent clearance of drug from plasma after extravascular 
administration
CNS Central nervous system
CPK Creatine phosphokinase
C-SSRS Columbia-Suicide Severity Rating Scale
CYP Cytochrome P450
DMC Data Monitoring Committee
DSM-[ADDRESS_1146133] European Clinical Trial Data Base
FDA ([LOCATION_002]) Food and Drug Administration
FOCBP Female(s) of child-bearing potential
GABA Gamma-aminobutyric acid
GCP Good Clinical Practice
GMR Geometric mean ratio
HbA1c Glycosylated hemoglobin
HDL High density lipoprotein
IAF Informed assent form
IB Investigatorâ€™s Brochure
ICF Informed consent form
ICH International Conference on HarmonisationClinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
17
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 17 Version 6.0, 07 Jul 2022ICMJE International Committee of Medical Journal Editors
ID IdentificationIEC Independent ethics committeeIMP Investigational medicinal productIND Investigational New Drug applicationINR International normalized ratioIRB Institutional review boardIRE Immediately reportable eventLDH Lactic dehydrogenaseLDL Low density lipoproteinMCH Mean corpuscular hemoglobinMDD Major depressive disorderMTD Maximum tolerated doseOPC Otsuka Pharmaceutical Co.
OTC Over the counter 
PK Pharmacokinetic(s)
PQC Product Quality ComplaintPT Prothrombin timePTSD Post-traumatic stress disorderQD Once dailyQTc Corrected QT intervalQTcF QT interval as corrected for heart rate by [CONTACT_6550]â€™s formulaRDW Red cell distribution widthSAE Serious adverse eventSAS Simpson Angus ScaleTEAE Treatment-emergent adverse event
t
maxTime to maximum (peak) plasma concentration
ULN Upper limit of normal
US [LOCATION_002] &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 18 Version 6.0, 07 Jul [ZIP_CODE] Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by 
[CONTACT_170501], 5th edition  (DSM-5) criteria as 
deficits in reciprocal social communication and social interaction (verbal and 
nonverbal).[ADDRESS_1146134] 
others.2 Approximately 20% of people with ASD exhibit irritability and aggression3 with 
> 50% exhibiting significant emotion dysregulation.[ADDRESS_1146135] the lives of people with ASD and their families. 
The prevalence of ASD in the pediatric population in the [LOCATION_002] (US) has 
increased over the past decade from estimates of 1 in 150 (0.67%) in 2000 to 1 in 
68 (1.46%) in 2012, with increases occurring in all racial, ethnic, and socioeconomic 
groups (Autism and Developmental Disabilities Monitoring Network, 11 sites).5 In 2011, 
the total costs per year for children with ASD in the US were estimated at between 
$11.5 billion and $60.[ADDRESS_1146136] parental productivity.6 
At present, the atypi[INVESTIGATOR_826295] (FDA) for the treatment 
of irritability associated with ASD.[ADDRESS_1146137] that children and adolescents are at higher risk than adults for 
experiencing sedation, acute extrapyramidal symptoms (EPS), withdrawal dyskinesia, 
and significant weight gain during treatment.8,9 For patients with ASD, the common side 
effects of these medications10 are likely to further isolate children and adolescents from 
social interaction. Thus, there is a need to identify additional efficacious agents for 
children with psychiatric disorders, especially considering the safety and tolerability 
issues that may be associated with the use of selected antipsychotics in children and 
adolescents.11 Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
19
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 19 Version 6.0, 07 Jul 2022Brexpi[INVESTIGATOR_4253] (also referred to as OPC-[ZIP_CODE] and Lu AF41156) is an atypi[INVESTIGATOR_826296]. 
Brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE]) is currently approved in the US as monotherapy for the 
treatment of schizophrenia and for use as an adjunctive therapy to antidepressants for the 
treatment of major depressive disorder (MDD) in adults. While the precise mechanism of 
action of brexpi[INVESTIGATOR_826297], the pharmacology 
of brexpi[INVESTIGATOR_572534] a combination of high binding affinity and 
functional activities at multiple monoaminergic receptors. 
1.1 Nonclinical Data
A complete description of the available data from nonclinical studies, including 
pharmacokinetics (PK) and toxicology studies in different animal species, can be found 
in the Investigatorâ€™s Brochure (IB).12 
1.2 Clinical Data
Pharmacokinetic (PK) and pharmacodynamic (PD) data, as well as data from 
schizophrenia and MDD are summarized below. A complete description of the available 
data from clinical trials can be found in the IB.12 
1.2.1 Pharmacokinetics/Pharmacodynamics
The PK of single and multiple doses of brexpi[INVESTIGATOR_826298], attention-deficit hyperactivity disorder (ADHD), and 
schizophrenia or schizoaffective disorder. Based on preclinical data and human clinical 
trials, brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE]) and one metabolite, DM-3411, were identified as the 
major analytes that are present in human plasma. In vitro, the activity of DM-3411 is 
17 times lower than that of brexpi[INVESTIGATOR_826299]. Both brexpi[INVESTIGATOR_34807]-3411 PK were linear following single oral doses 
of brexpi[INVESTIGATOR_4253] 0.2 to 8 mg to healthy subjects. The terminal phase elimination half-life 
of brexpi[INVESTIGATOR_34807]-3411 was 48.3 to 80.8 hours and 48.6 to 77.5 hours, 
respectively. The median time to maximum (peak) plasma concentration (t max) occurred 
at approximately [ADDRESS_1146138] its rate and extent of absorption.
Steady state PK also appeared to be linear following multiple daily doses of 
brexpi[INVESTIGATOR_34808] 0.5 to 2 mg to healthy subjects. The accumulation factor 
based on maximum (peak) plasma concentration and area under the concentration-time Clinical Study Report 331-201-[ADDRESS_1146139] observable concentration at time t was approximately 4 times. 
After multiple dose administration of brexpi[INVESTIGATOR_4253] (1 to 12 mg/day) to subjects with 
schizophrenia or schizoaffective disorder, brexpi[INVESTIGATOR_34807]-3411 mean terminal 
elimination half-life at steady state was 95.4 and 89.3 hours, respectively; median t max 
was 3.0 and 8.0 hours, respectively.
In drug interaction trials in healthy subjects, brexpi[INVESTIGATOR_788431] P450 (CYP) 3A4 and CYP2D6 isozymes and was not an inhibitor of 
CYP3A4, CYP2B6, CYP2D6, or P-glycoprotein. Co-administration of potent CYP3A4 
or CYP2D6 inhibitors with brexpi[INVESTIGATOR_34810] a 2-fold higher exposure and 
about a 1.5-fold increase in the terminal elimination half-life of brexpi[INVESTIGATOR_4253].
In a single-dose trial in healthy subjects, approximately 46.0% and 24.6% of 
administered radioactivity following an oral dose of 14C-brexpi[INVESTIGATOR_34811], respectively. In this same trial, brexpi[INVESTIGATOR_788432]. Brexpi[INVESTIGATOR_657414] (ï‚³  99.8%) 
in vitro.
In Trial 331-201-[ZIP_CODE], a phase 1 pediatric trial to assess PK and safety of oral 
brexpi[INVESTIGATOR_826300] 6 to < 13 years old with central nervous system (CNS) 
disorders, mean apparent clearance of drug from plasma after extravascular 
administration (CL/F) of brexpi[INVESTIGATOR_826301] 1.5 or 3 mg in children 10 to < 13 years old 
was comparable with that observed in adults following a single dose of brexpi[INVESTIGATOR_4253] 
2 mg. Dose proportionality was observed within treatment cohorts (ie, within the same 
age range) and children in the younger age group (6 to < 10 years old) appeared to have 
slightly higher brexpi[INVESTIGATOR_34807]-3411 exposure and lower brexpi[INVESTIGATOR_826302]/F as 
compared with children in the older group (10 to < 13 years old).
Trial 331-10-233 was a phase 1, multicenter, open-label dose escalation trial to assess the 
safety, tolerability, and PK of oral brexpi[INVESTIGATOR_826303]. In Trial 331-10-233, overall systemic exposure was 
measured by [CONTACT_2715]-normalized maximum concentration at steady state ( Cmax,ss ) and area 
under the plasma concentration-time curve to the last observable concentration (AUCÏ„), 
and was slightly higher (geometric mean ratio [GMR] adult/adolescent: 0.765 and 0.904, 
respectively), and CL/F was slightly lower (GMR adult/adolescent: 1.11) in adolescents 
compared to adults in the more important PK evaluable population. For the less important 
PK population, slightly lower dose-normalized AUCs from time 0 to 24 hours (AUC 0-24h) 
(GMR adult/adolescent: 1.05), and slightly higher dose-normalized maximized Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
21
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 21 Version 6.0, 07 Jul 2022concentrations (C max) (GMR adult/adolescent: 0.904) were observed in adolescents when 
compared to adults. The difference in the results for the 2 populations may be due to 
potential noncompliance, especially in the lower dose groups (0.5 and 1.0 mg), when 
dosing was not under medical supervision.
1.2.2 Schizophrenia
The efficacy of brexpi[INVESTIGATOR_788435] 2 completed placebo-controlled trials 
(Trials 331-10-230 and 331-10-231), a long-term maintenance trial (Trial 331-10-232), 
and a long-term safety trial (Trial 331-10-237), and was approved for the treatment of 
schizophrenia in adults (ages 18 to 65 years) by [CONTACT_3557] 10 Jul 2015. 
Brexpi[INVESTIGATOR_826304] 
13 to 17 years old in the double-blind Trial 331-10-234 and open-label Trial 331-10-236.
1.2.3 Major Depressive Disorder
The efficacy of brexpi[INVESTIGATOR_788437] 3 completed placebo-controlled trials (Trials 331-10-227, 331-10-228, and 
331-13-214) and a long-term, open-label safety trial (Trial 331-10-238). A double-blind, 
placebo-controlled trial to evaluate the safety, efficacy, and tolerability of brexpi[INVESTIGATOR_4253] 
(Trial 331-201-[ZIP_CODE]) is currently ongoing. Brexpi[INVESTIGATOR_826305] 
10 Jul 2015 in adult patients for use as an adjunctive therapy to antidepressants for the 
treatment of MDD.
1.2.4 Autism Spectrum Disorder
There is 1 planned double-blind trial (Trial 331-201-[ZIP_CODE]) in pediatric subjects with 
ASD. 
1.3 Known and Potential Risks and Benefits
As of 17 Apr 2021, the brexpi[INVESTIGATOR_444410] a total 
of 97 clinical trials conducted in North America, Latin America, Europe, and Asia 
(77 completed and 20 ongoing). This total includes 77 trials conducted under US 
Investigational New Drug applications (INDs) (65 completed and 12 ongoing) for 
schizophrenia, adjunctive treatment of MDD, adjunctive treatment of ADHD, agitation 
associated with dementia of the Alzheimerâ€™s type (AAD), post-traumatic stress disorder 
(PTSD), or bipolar disorder; and 20 non-US IND trials (12 completed and 8 ongoing in 
China, Japan, and Canada) conducted in healthy subjects, subjects with schizophrenia, 
subjects with MDD, and subjects with AAD.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
22
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 22 Version 6.0, 07 Jul 2022Safety data are available from the 76 completed clinical trials. The total number of 
subjects exposed to either single or multiple doses of brexpi[INVESTIGATOR_826306] 
9831 subjects in trials conducted under US IND applications and 876 subjects 
(collectively) in non-US IND trials conducted in Japan, China, and South Korea.
Combined data from the completed phase 1 clinical trials indicate that the maximum 
tolerated dose (MTD) for healthy adult subjects was determined to be 6 mg after single-
dose administration and 2 mg after once-daily, multiple-dose (14 days) administration. 
The MTD of brexpi[INVESTIGATOR_826307], MDD, AAD, ADHD, or 
bipolar disorder has not been established. Data from completed phase 1 clinical trials 
indicate that brexpi[INVESTIGATOR_826308] 12 mg/day in subjects 
with schizophrenia or schizoaffective disorder; up to 4 mg/day when coadministered with 
marketed antidepressant therapy in subjects with MDD; up to 3 mg/day in elderly 
subjects (70 - 85 years of age) with MDD; and up to 4 mg/day when coadministered with 
marketed stimulant therapy in subjects with ADHD. 
Overall, 69.6% of subjects who received brexpi[INVESTIGATOR_826309] 1 treatment-emergent adverse event 
(TEAE, with â‰¥ 2% incidence in total brexpi[INVESTIGATOR_34848]). The most 
frequently reported TEAEs (incidence â‰¥ 5% of the total brexpi[INVESTIGATOR_826310]) in all subjects who received brexpi[INVESTIGATOR_444415] 
(11.7%), headache (8.9%), insomnia (7.5%), akathisia (7.3%), somnolence (6.0%), and 
dizziness (5.2%). In the total placebo group, headache (8.4%) was the most frequently 
reported TEAE (incidence â‰¥ 5% of subjects). The majority of TEAEs reported in [ADDRESS_1146140] been reported in the brexpi[INVESTIGATOR_826311] 17 Apr 2021: [ADDRESS_1146141] 
(IMP).
Serious TEAEs have been reported for 415 subjects who received brexpi[INVESTIGATOR_4253] (either 
alone or coadministered with another medication) in the 61 completed trials conducted 
under the US INDs, and in 58 subjects in the 12 completed non-US IND trials. Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
23
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 23 Version 6.0, 07 Jul 2022Overall, 9.3% of subjects who received brexpi[INVESTIGATOR_4253] (either alone or coadministered 
with another medication) and 4.5% of subjects who received placebo (either alone or 
coadministered with another medication) discontinued from IMP due to TEAEs in 61 
pooled completed brexpi[INVESTIGATOR_826312] 17 Apr 2021. Overall, 10.6% of subjects who received brexpi[INVESTIGATOR_826313]-US IND trials.    
In the phase 1, pediatric Trial 331-201-[ZIP_CODE], brexpi[INVESTIGATOR_826314] 0.75 to 1.5 mg in subjects 6 to < 10 years old and 1.5 to 3 mg in 
subjects 10 to < [ADDRESS_1146142] frequently reported TEAE (> [ADDRESS_1146143]) 
was nausea. Additionally, in Trial 331-10-233, multiple oral doses of 0.5 to 4 mg/day 
brexpi[INVESTIGATOR_826315] 13 to 17 years old with schizophrenia or other related 
psychiatric disorders were safe and well tolerated. The observed IMP-related TEAEs 
were similar in both trials.
The recommended dose ranges are as follows: 2 to 4 mg/day for the treatment of 
schizophrenia in adults and 2 to 3 mg/day in adult subjects with MDD. The following 
dose ranges of brexpi[INVESTIGATOR_826316] (by 
[CONTACT_35151]): 0.5 to 3 mg/day in adult subjects with AAD, 1 to 3 mg/day in adult subjects 
with PTSD, and 2 to 4 mg/day in adult subjects with bipolar disorder.
Please refer to the current IB for a detailed summary of available nonclinical and clinical 
safety data.12 
2 Trial Rationale and Objectives
2.1 Trial Rationale
Trial 331-201-[ZIP_CODE] is being conducted to evaluate the long-term safety and tolerability 
of brexpi[INVESTIGATOR_826317] 
(ages 5 - 17 years) who have completed the corresponding double-blind, phase [ADDRESS_1146144] been conducted to investigate the PK, safety, and tolerability of 
brexpi[INVESTIGATOR_826318]: in Trial 331-10-233, subjects 13 to 17 years old received multiple daily doses Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
24
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 24 Version 6.0, 07 Jul 2022of brexpi[INVESTIGATOR_4253] 0.5 to 4 mg; and in Trial 331-201-[ZIP_CODE], subjects 6 to 13 years old 
received single doses of brexpi[INVESTIGATOR_4253] 0.75, 1.5, or 3 mg.
In order to guide dose selection of brexpi[INVESTIGATOR_826319] 5 to 17 years of age with 
irritability associated with ASD, a population PK model was developed using PK data from the 2 PK trials in children and adolescents (Trial 331-10-233 and Trial 331-201-[ZIP_CODE]) and 3 PK trials in healthy adults or adults with schizophrenia (Trials , 
 and ) in healthy or schizophrenic subjects. In this model, 
clearance and volume of distribution were allometrically scaled by [CONTACT_18694] (raised to the power of 0.75 for clearance, and 1 for volume of distribution); poor and ultra-rapid CYP2D6 metabolizers were excluded in the analysis data; when needed for simulation, the effect of CYP2D6 metabolic status on clearance can be imputed using the value reported in the adult population PK model previously submitted. The allometrically scaled PK model adequately described the PK data in adults, children, and adolescents. Pharmacokinetic simulations were performed using this model to predict systemic exposure of brexpi[INVESTIGATOR_826320]. Target exposure used for the simulations of ASD in subjects 5 to 17 years 
of age was similar to that of the adult subjects with MDD (0.5 - 3 mg/day).
Brexpi[INVESTIGATOR_826321], represented AUC Ï„ were simulated and the 5th, median, 
and 95th percentiles were compared between children or adolescents 5 to 17 years of age 
and adult subjects with MDD. Based on the simulation result and clinical considerations, a weight cutoff at 50 kg was suggested to make sure subjects receive appropriate dose; and the following was observed:
â€¢AUCÏ„ following 0.25 mg in children and adolescents <50 kg and AUC Ï„ following 
0.5 mg in children and adolescents â‰¥ 50 kg are comparable with that following 
0.5 mg in adult subjects.
â€¢AUCÏ„ following 1.5 mg in children and adolescents <50 kg and AUC Ï„ following 
3 mg in children and adolescents â‰¥ 50 kg are comparable with that following 3 mg in 
adult subjects.
Based on PK simulation, starting and maximum doses were determined. Pharmacokinetic 
profiles following the proposed titration/dosing schedule was also simulated and 
compared with the titration schedule in ongoing trials in adult subjects with bipolar I disorder. The dosing schedules for this trial, based on simulation results and clinical considerations are shown in Table 3.2-1 . &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
Table 3.2-1CCI
CCI CCI
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 25 Version 6.0, 07 Jul [ZIP_CODE].3 Trial Objectives
The primary objective is to assess the long-term safety and tolerability of brexpi[INVESTIGATOR_826322].
The secondary objective is to assess the long-term efficacy of brexpi[INVESTIGATOR_826323].
3 Trial Design
This is a multicenter, open-label trial designed to assess the long-term safety and 
tolerability of oral brexpi[INVESTIGATOR_826324]. The trial is planned to be conducted on an outpatient basis. Enrollment into the 
trial will be drawn from eligible subjects who completed the treatment period in the 
double-blind, phase 3 efficacy trial, Trial 331-201-[ZIP_CODE] (8 weeks of treatment) and, in 
the investigatorâ€™s judgment, could potentially benefit from continued investigational 
treatment with oral brexpi[INVESTIGATOR_4253]. 
The trial will be conducted as follows:
Screening/Baseline: Subjects who completed the treatment period of the double-blind 
trial and were deemed compliant with the protocol will be screened for eligibility at the 
last visit of the double-blind trial (Week 8). A separate fully executed informed 
consent/assent will be obtained for Trial 331-201-[ADDRESS_1146145] visit of the double-
blind trial will serve as the baseline measures for Trial 331-201-[ZIP_CODE] for any assessment 
that is not unique to the open-label trial. Medical history will be updated, if necessary.
Open-label Treatment Phase: Eligible subjects from Trial 331-201-[ADDRESS_1146146] with trial personnel using online communication tools 
which incorporate telemedicine. During virtual interactions (and at any other time), the Clinical Study Report 331-201-[ADDRESS_1146147] and determine if an additional in-office 
visit for a physical evaluation is required at the discretion of the investigator.
Follow-up: Subjects will have a follow-up contact 21 (Â± 2) days after the last dose of 
open-label brexpi[INVESTIGATOR_4253].
3.1 Type/Design of Trial
A schematic of the trial design is provided in Figure 3.1-1.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
27
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 27 Version 6.0, 07 Jul 2022 
Figure 3.1-1 Trial Design Schematic
Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
28
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 28 Version 6.0, 07 Jul [ZIP_CODE].2 Trial Treatments
Brexpi[INVESTIGATOR_826325]-resistant 
blister cards, each containing sufficient tablets for 7 (+ 2) days. All doses of open-label 
brexpi[INVESTIGATOR_826326]. Every effort should be made to administer the open-label brexpi[INVESTIGATOR_826327], preferably in the morning. 
The first dose of open-label brexpi[INVESTIGATOR_826328]-blind IMP is taken in the parent trial so that treatment continues without 
interruption. Whenever possible, it is anticipated that the last dose of IMP in the double-
blind, phase 3 efficacy trial will be taken on the day of the baseline visit for the open-
label trial. Subjects should not be dosed using double-blind and open-label IMP on the 
same day.  
Titration/Dosing Instructions:
Subjects will follow the titration/dosing schedule in Table 3.2-1. As in the parent trial, the 
tit
ration/dosing schedule will be based on body weight. Body weight at the Week 8 
double-blind visit/baseline visit for Trial 331-201-[ADDRESS_1146148] at this time will determine titration/dose 
requirements throughout the trial. Those subjects with body weight < 50 kg will receive a 
target dose range of 1 to 1.5 mg, and those subjects with body weight â‰¥ 50 kg will receive 
a target dose range of 1.5 to 3 mg.
Table 3.2-1 Open-label Titration/Dosing Schedule for Subjects with 
Irritability Associated with ASDa
Trial Day Number of Days on 
IMPBrexpi[INVESTIGATOR_826289]
(Body Weight)
< 50 kg (QD) â‰¥ 50 kg (QD)
Days 1 to 3 3 0.25 mg 0.5 mg 
Days 4 to 7 4 0.5 mg 1.5 mg 
Days 8 to 14 7 1 mg 2 mg 
Starting at Day 15 
(earliest opportunity to 
increase to maximum 
dose within target dose 
range)Based on investigator 
discretion to change 
dose based on 
therapeutic effect or 
tolerability1 or 1.5 mg 1.5, 2, or 3 mg 
QD = once daily.
aDose titrations will be performed in conjunction with a trial visit and therefore, trial visit windows are 
allowed for the titration schedule. Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
29
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 29 Version 6.0, 07 Jul 2022Subjects with body weight < [ADDRESS_1146149]. 
Subjects with body weight â‰¥ [ADDRESS_1146150]. 
For all subjects, doses can be down-titrated due to tolerability based on investigator 
judgment. Subjects < 50 kg should receive a dose of 1.5 mg before decreasing the dose to 
1 mg. Subjects â‰¥ [ADDRESS_1146151] with body weight < [ADDRESS_1146152] with body weight â‰¥ [ADDRESS_1146153]â€™s home. The IMP for dose increases or decreases occurring between 
scheduled visits will be dispensed as an unscheduled visit and accommodations arranged 
to have IMP received by [CONTACT_423]/caregiver, either by [CONTACT_826358][INVESTIGATOR_826329]. Instructions will be supplied to the subject/caregiver by [CONTACT_10665]/team support staff 
regarding any dosing changes.  Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
30
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 30 Version 6.0, 07 Jul [ZIP_CODE].3 Trial Population
3.3.1 Description of Population
The trial population will include children and adolescent rollover subjects from the 
double-blind, phase 3 efficacy trial of brexpi[INVESTIGATOR_123107]: Trial 331-201-[ZIP_CODE] 
(irritability in ASD). 
Subjects with a DSM-[ADDRESS_1146154] identification (ID) numbers from the parent trial and are 
required to sign a new informed consent form (ICF) and assent form for this trial, as 
applicable.
3.4 Eligibility Criteria
3.4.1 Informed Consent/Assent
Informed consent/assent will be freely obtained from all subjects (or their guardian or 
legally acceptable representative, as applicable for local laws). Consent and assent will be 
documented on an electronic or written ICF and informed assent form (IAF). The 
ICF/IAF will be approved by [CONTACT_257726]/independent ethics 
committee (IRB/IEC) that approves this protocol. Subjects who are too young to sign an 
ICF/IAF either via wet signature [CONTACT_169352] (e-signature) will provide 
informed assent per local law, and the subject must be able to understand that he or she 
can withdraw from the trial at any time and for any reason.
Each ICF/IAF will comply with the International Conference on Harmonisation (ICH) 
Good Clinical Practice (GCP) Guideline13 and local regulatory requirements. The 
investigator will ensure that the sponsor reviews and authorizes any site-specific ICF/IAF 
used in the trial before submission to the IRB/IEC. 
Investigators may discuss trial availability and the possibility for entry with a potential 
subject without first obtaining consent/assent. However, informed consent/assent must be 
obtained and documented prior to initiation of any procedures that are performed solely 
for the purpose of determining eligibility for research, including withdrawal from current 
medication(s). Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
31
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 31 Version 6.0, 07 Jul 2022Potential subjects are free to refuse entry into the trial, or withdraw from the trial at any 
time, without justification, and there will be no consequences to their further care.
Once appropriate essential information has been provided and fully explained in 
laymanâ€™s language to the subject and/or his/her parent/legal guardian or legally 
acceptable representative, as applicable by [CONTACT_093] (or a qualified designee), and 
it has been documented that the subject and his/her parent/legal guardian or legally 
acceptable representative has had the opportunity to ask questions, the IRB/IEC-approved 
written ICF/IAF will be signed and dated by [CONTACT_423], the subjectâ€™s legally acceptable 
representative (eg, guardian), and the person obtaining consent/assent (investigator or 
designee), as well as by [CONTACT_78629]/IEC. The subject will 
receive a copy of the signed ICF/IAF; the original shall be kept on file by [CONTACT_1275].
At sites where the electronic ICF/IAF application is used, prospective trial participants 
will be provided with controlled access to the application by [CONTACT_444485]. When the trial 
site staff and the participant agree that the participant has enough information to make an 
informed decision to participate, the participant will electronically sign the ICF/IAF in 
the electronic ICF application and an electronic date and timestamp will be applied to the 
signature. The subject will be given a printed, signed copy of the ICF/IAF. Any other 
parties required by [CONTACT_1201]/IEC (trial site staff, witnesses, or legally authorized 
representative) are also required to sign electronically and these signatures will be stored 
with the electronic ICF/IAF in accordance with the ICH GCP Guideline and local 
regulatory requirements/guidelines. These signatures cannot be altered, removed, or 
copi[INVESTIGATOR_530]. At sites where the electronic ICF/IAF application is not used, paper consent and 
assent forms will be signed after trial site staff and the participant agree that the 
participant has enough information to make an informed decision to participate. Any 
other parties required to provide signatures will also sign the paper forms, and the forms 
will be stored in accordance with the ICH GCP Guideline and local regulatory 
requirements/guidelines.
Subjects or their parent/legal guardian or legally acceptable representative, as applicable 
for local laws, may be asked to sign additional ICFs/IAFs if the protocol is amended and 
the changes to the protocol result in additional information that needs to be provided to 
the subjects, so that they can make a knowledgeable and voluntary decision on trial 
participation. Clinical Study Report 331-201-[ADDRESS_1146155]. Subjects who turn age 18 (or the age of adulthood as specified by [CONTACT_147655]) during the trial must sign a new ICF at that time.
In addition to the English version of the ICF/IAF, the documents may also be translated 
into local languages for use in this trial. Translation with back-translation for 
confirmation will be utilized to ensure accuracy.
3.4.2 Inclusion Criteria
Subjects are required to meet the inclusion criteria presented in Table 3.4.2-1.
Table 3.4.2-1 Inclusion Criteria
1. Subjects who, in the opi[INVESTIGATOR_871], could potentially benefit from administration of 
oral brexpi[INVESTIGATOR_826330] 331-201-[ZIP_CODE].
2. Male and female subjects 5 to 17 years of age, inclusive, at the time of informed consent/assent. 
Subjects who turned 18 years old during Trial 331-201-[ZIP_CODE] are permitted in this trial.
3. Written informed consent/assent obtained from a legally acceptable representative (eg, guardian) or 
subject prior to the initiation of any protocol-required procedures. In addition, the subject must 
provide informed assent at screening and must be able to understand that he or she can withdraw 
from the trial at any time. All informed consent/assent procedures must be in accordance with the 
trial siteâ€™s IRB/IEC and local regulatory requirements.
4. Ability, in the opi[INVESTIGATOR_14371], of the subject or the subjectâ€™s legally acceptable 
representative (eg, guardian) or caregiver(s) to understand the nature of the trial and follow 
protocol requirements, including the prescribed dosage regimens, tablet ingestion, and 
discontinuation of prohibited concomitant medications, to read and understand the written word in 
order to complete subject-reported outcomes measures, and to be reliably rated on assessment 
scales.
3.4.[ADDRESS_1146156] from participation in 
Trial 331-201-[ZIP_CODE]; however, continual lack of compliance with the visit schedule, trial 
assessments, or treatment regimen in the prior double-blind trial would be considered a substantial 
violation that would result in exclusion from Trial 331-201-[ZIP_CODE]. The medical monitor should be 
contact[CONTACT_657619] a subjectâ€™s eligibility.
2. Sexually active males or FOCBP who do not agree to practice [ADDRESS_1146157] be used: vaginal diaphragm, intrauterine device, birth 
control pi[INVESTIGATOR_4382], birth control implant, birth control depot injection, condom with spermicide, or sponge 
with spermicide. Clinical Study Report 331-201-[ADDRESS_1146158]-feeding and/or who have a positive pregnancy test result prior to receiving 
IMP.
4. Subjects who, in the opi[INVESTIGATOR_871], medical monitor, or sponsor, should not participate 
in the trial.
5. Subjects who are siblings, or are unrelated and live in the same household, cannot simultaneously 
participate in the trial.
FOCBP = females of child-bearing potential
Subjects must agree to restrictions to medications and lifestyle as described in Section [ADDRESS_1146159] endpoints for clinical trials and trials of 
antipsychotic drugs:
â€¢The frequency and severity of adverse events (AEs), serious AEs (SAEs), and 
discontinuation from the trial due to AEs.
â€¢Change from baseline to postbaseline time points in 1) vital sign measurements, 
2) electrocardiogram (ECG) parameters, 3) clinical laboratory tests (including prolactin) and urinalysis, and 4) physical examination findings.
â€¢Analysis of potential suicide events recorded on the Columbia-Suicide Severity 
Rating Scale (C-SSRS). 
â€¢Changes from baseline to postbaseline time points in results from EPS scales 
(Simpson Angus Scale [SAS], Abnormal Involuntary Movement Scale [AIMS], and Barnes Akathisia Rating Scale [BARS]).
â€¢Percentage of subjects with clinically significant changes in weight (gain or loss) 
from baseline to specified time points. 
â€¢Time to discontinuation.
3.5.2 Secondary Endpoints
â€¢Change from baseline to Week [ADDRESS_1146160] -â€“ Irritability 
(ABC-I) subscale score.
â€¢Change from baseline to Week 26 in Clinical Global Impression - Severity (CGI-S) 
scale score targeted on irritability.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 34 Version 6.0, 07 Jul [ZIP_CODE].6 Measures to Minimize/Avoid Bias
Not applicable; this is an open-label trial.
3.7 Trial Procedures
Trial assessment time points are summarized in Table 3.7-1 .&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
Table 3.7-1CCI
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 35 Version 6.0, 07 Jul 2022Table 3.7-1 Schedule of Assessments - Rollover Subjects from Trial 331-201-[ZIP_CODE]
26-week Open-label Treatment Period EOTFollow-
up
AssessmentScreening/ 
Baseline
Last visit 
from Trial 
331-201-
[ZIP_CODE]/
Baseline
for Trial
331-201-
00191Week 
1
(Day 7 
Â± 2 
days)
Virtual 
or In 
officeWeek 
2
(Day 
14 Â± 2 
days)
In 
officeWeek 
3
(Day 21 
Â± 2 
days)
Virtual 
or In 
officeWeek 
4
(Day 28 
Â± 2 
days)
Virtual 
or In 
officeWeek 
8
(Day 56 
Â± 2 
days)
Virtual 
or In 
officeWeek 
14
(Day 
98 Â± 
2 
days)
In 
officeWeek 
18 
(Day 
126 Â± 2 
days)
Virtual 
or In 
officeWeek 22 
(Day 154 
Â± 2 days)
Virtual 
or In 
officeWeek 
26/ ET
(Day 
182 Â± 
2 
days)
In 
office21 (Â± 2) 
days 
after 
last 
dose of 
IMP
By [CONTACT_826359]/assent, update medical history, as neededX
Section 3.4.1
Prior medications X Section 3.7.4
Inclusion/exclusion 
criteriaX
CGI-S X X X X X X X X X X Section [IP_ADDRESS]
SAS, AIMS, & 
BARSXX X X Section [IP_ADDRESS]
C - S S R S X X X XXX X X XX Section [IP_ADDRESS].4
ABC X X X XXX X XX X Section [IP_ADDRESS]
Physical 
examinationX X Section [IP_ADDRESS].[ADDRESS_1146161] circumferenceXX X
Section [IP_ADDRESS].1
Height X X X Section [IP_ADDRESS].1
Vital signs X X X X X X X X X X Section [IP_ADDRESS].2&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 36 Version 6.0, 07 Jul 2022Table 3.7-1 Schedule of Assessments - Rollover Subjects from Trial 331-201-[ZIP_CODE]
26-week Open-label Tre
atment Period EOTFollow-
up
Assess
mentScreening/ 
Baseline
Last visit 
from Trial
 
331-201-
[ZIP_CODE]/ 
Baseline 
for Trial 
331-201-
00191Week 
1
(Day 7 
Â± 2 
days)
Virtual 
or In 
officeWeek 
2
(Day 
14 Â± 2 
days)
In 
officeWeek 
3
(Day 21 
Â± 2 
days)
Virtual 
or In 
officeWeek 
4
(Day 28 
Â± 2 
days)
Virtual 
or In 
officeWeek 
8
(Day 56 
Â± 2 
days)
Virtual 
or In 
officeWeek 
14
(Day 
98 Â± 
2 
days)
In 
officeWeek 
18 
(Day 
126 Â± 2 
days)
Virtual 
or In 
officeWeek 22 
(Day 154 
Â± 2 days)
Virtual 
or In 
officeWeek 
26/ ET
(Day 
182 Â± 
2 
days)
In 
office21 (Â± 2) 
days 
after 
last 
dose of 
IMP
By [CONTACT_826360] X X X Section [IP_ADDRESS]
Clinical laboratory 
tests (hematology, 
serum chemistry, 
and urinalysis)X X X Section [IP_ADDRESS]
HbA1c X X X Section [IP_ADDRESS]
Prolactin X X X Section [IP_ADDRESS]
Urine pregnancy 
testX X X Section [IP_ADDRESS]
ACTH X X Section [IP_ADDRESS]
Cortisol X X Section [IP_ADDRESS]
TSH with reflex to 
free T4 if abnormalX X X Section [IP_ADDRESS]
Coagulation 
parametersX X Section [IP_ADDRESS]
Adverse events X X X X X X X X X X X Section 5
Concomitant 
medicationsX X X X X X X X X X X Section 3.7.4
Dispense IMP X X X X X X X X X
IMP accountability X X X X X X X X X XClinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
37
Protocol 331-201-[ZIP_CODE]
Confidential - Proprietary Information 37 Version 6.0, 07 Jul 2022ABC = Aberrant Behavior Checklist; ACTH = Adrenocorticotropic hormone; AIMS =Abnormal Involuntary Movement Scale; BARS = Barnes  Akathisia 
Rating Scale; BP = blood pressure; CGI -S = Clinical Global Impression - Severity of Illness scale; C-SSRS = Columbia-Suicide Severity Rating Scale; 
ECG = electrocardiogram; ET = early termination; ; ; SAS = Simpson-Angus Scale; TSH = thyroid-stimulating hormone.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI CCI
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 38 Version 6.0, 07 Jul [ZIP_CODE].7.1 Schedule of Assessments
[IP_ADDRESS] Screening and Baseline
Rollover subjects who do not qualify for the open-label trial at the screening/baseline 
visit may not be rescreened at a later date. If results of clinical laboratory tests from the 
last visit of the prior double-blind trial are not available to assess eligibility, the 
assessment for the affected criteria should be based on the last available measurement 
during the double-blind trial. Results from the last visit of the double-blind trial should be 
reviewed when they become available and action should be taken if there are any 
clinically significant and/or exclusionary values. 
Screening for rollover subjects occurs simultaneously with baseline at the 
end-of-treatment (Week 8) of Trial 331-201-[ZIP_CODE] (Table 3.7-1). Subjects and their 
parent/legal guardian must sign the ICF/IAF for the open-label trial before any 
procedures specific to Trial 331-201-[ADDRESS_1146162] ID number assigned in the parent trial. 
Screening/baseline values will be derived from the last visit of the double-blind phase 3 
trial for the following assessments (as appropriate): CGI-S, SAS, AIMS, BARS, C-SSRS, 
PARS, PedsQL, ABC, physical examination, body weight, height, waist circumference, 
vital signs, ECG, clinical laboratory tests (including prolactin), urine drug screen, and 
urine pregnancy test. The only additional procedures to be performed for rollover 
subjects at screening/baseline of the open-label trial are as follows:
â€¢An assessment of all inclusion and exclusion criteria will be made to determine 
the subjectâ€™s eligibility for the trial.
â€¢Medical history from the parent trial will be retained, but will be updated if 
necessary.
â€¢Concomitant medications will be reviewed to assure that the subject is not 
receiving any prohibited medications.
â€¢AE recording will begin with the signing of the ICF/IAF for Trial 331-201-[ZIP_CODE].
â€¢If the subject remains eligible for the trial after completion of the baseline 
evaluations, trial personnel will use eSource to obtain an IMP assignment. 
â€¢The IMP will be dispensed to the subject and the subject will be advised to begin 
dosing from this card the next day.
All subjects will be assessed at various scheduled clinic visits as described below. Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
39
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 39 Version 6.0, 07 Jul [ZIP_CODE].7.1.2 Weeks 1, 2, 3, 4, 8, 14, 18, and 22
Evaluations will be performed at Weeks (Â± 2 days) 1, 2, 3, 4, 8, 14, 18, and [ADDRESS_1146163] with trial personnel using 
online communication tools which incorporate telemedicine. During virtual interactions 
(and at any other time), the trial personnel will be able to assess the subject and determine 
if an additional in-office visit for a physical evaluation is required at the discretion of the 
investigator. The telecommunication equipment is supplied to all caregivers and subject 
pairs. The equipment will be returned at the end of trial participation. 
Visits are to occur within Â± 2 days of the target visit date. All required evaluations will be 
performed as described in the Schedule of Assessments (Table 3.7-1). The following 
should also be noted: 
â€¢Subjects will have their IMP dispensed at a clinic visit or delivered to the home 
for a virtual visit. Pi[INVESTIGATOR_826331].
â€¢IMP accountability will be performed
[IP_ADDRESS] End of Treatment (Week 26 or Early Termination) 
The treatment period for the entire trial will conclude at the Week 26 visit. This in clinic 
visit is to occur within Â± [ADDRESS_1146164] be completed at the early 
termination (ET) visit. All required evaluations will be performed as described in the 
Schedule of Assessments (Table 3.7-1). The following should also be noted: 
â€¢Trial personnel will register completion or discontinuation from the trial in 
eSource.
â€¢IMP accountability will be performed.Clinical Study Report 331-201-[ADDRESS_1146165] 
21 (Â± 2) days after the last dose of IMP to assess any new or ongoing AEs and to record any concomitant medications. Depending upon the type of follow-up required, other evaluations or tests may be conducted or performed.
3.7.[ADDRESS_1146166]â€™s trial records should substantiate the ratings. Training, certification (if applicable), and materials for rating will be provided.  
[IP_ADDRESS] Aberrant Behavior Checklist 
The ABC-I is [ADDRESS_1146167] in this trial.
14,15
[IP_ADDRESS] Clinical Global Impression - Severity of Illness Scale 
The severity of illness for subjects with ASD will be rated using the CGI-S with a focus 
on symptoms of irritability.16 To perform this assessment, the rater or investigator will 
answer the following question: â€œConsidering your total clinical experience with this 
particular population, how ill is the patient at this time with regard to symptoms of 
irritability?â€ Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients.  &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
1415
16
CCI
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 41 Version 6.0, 07 Jul 2022&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 42 Version 6.0, 07 Jul [ZIP_CODE].7.3 Safety Assessments
[IP_ADDRESS] Adverse Events
Refer to Section 5, Reporting of Adverse Events. 
[IP_ADDRESS]
Clinical Laboratory Assessments
Table [IP_ADDRESS]-[ADDRESS_1146168] for all subjects in 
this trial. A central laboratory designated by [CONTACT_826361]. The central laboratory should be used for all laboratory 
testing whenever possible (including unscheduled and follow-up laboratory tests, if 
needed). In cases where an immediate result is required for a particular laboratory test, 
the sample should be divided and sent to both a local laboratory and the designated 
central laboratory. Urine will be collected, and blood will be drawn from each subject at 
screening and then at the scheduled visits designated in the Schedule of Assessments 
(Table 3.7-1). The results of these t ests must be reviewed by t he investigator prior to 
initiation of IMP. 
Urine drug screens and blood alcohol tests will be conducted at the discretion of the 
investigator.
Subjects should be fasting for a minimum of [ADDRESS_1146169] is not fasting at a visit, the blood draw should still be performed, 
and the status documented as nonfasting on the laboratory requisition sheet. Reports from 
the central laboratory will be retained electronically within the lab vendor's online portal 
and assessed by [CONTACT_826362].Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
43
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 43 Version 6.0, 07 Jul 2022Table [IP_ADDRESS]-1 Clinical Laboratory Assessments
Hematology:
Hematocrit
Hemoglobin
Mean corpuscular hemoglobin concentration 
Mean corpuscular volume 
Platelets
RBC count
WBC count with differential 
MCH
RDW
RBC morphology
Urinalysis:
Appearance
Color 
Blood
Glucose
Microscopic analysis, WBC/RBC counts per high 
powered field
pH
Protein
Specific gravity
Urine drug screen:
Amphetamines
Barbiturates
Opi[INVESTIGATOR_826332]:
Albumin
Alkaline phosphatase
ALT
AST
Bicarbonate 
Bilirubin, total 
BUN 
Calcium
Chloride
Cholesterol (total, LDL, HDL)
CPK
Creatinine
GGT
Glucose
Insulin
LDH
Potassium
Protein, total 
Sodium
Triglycerides
Uric acid
Additional Tests:
Blood alcohol test
Blood HbA1c
Urine or serum pregnancy for all FOCBP
Serum TSH, with reflex to free T 4 if TSH is 
abnormal
ACTH 
Cortisol
Serum prolactin 
Coagulation Parameters:
PT
aPTT
INR
aPTT = activated partial thromboplastin time; ALT = alanine aminotransferase; AST = aspartate 
aminotransferase; BUN = blood urea nitrogen; CPK = creatine phosphokinase; INR = international 
normalized ratio; GGT = gamma glutamyl transferase; HbA1c = glycosylated hemoglobin; HDL = high 
density lipoprotein; LDH = lactic dehydrogenase; LDL = low density lipoprotein, MCH = mean 
corpuscular hemoglobin; PT = prothrombin time; RBC = red blood cell; RDW = red cell distribution width; 
WBC = white blood cell.
The total volume of blood to be collected during the trial will be documented in the 
ICF/IAF.Clinical Study Report 331-201-[ADDRESS_1146170] will be conducted in all females of child-bearing potential 
(FOCBP) prior to trial intervention; results must be available prior to the administration 
of the IMP. A confirmatory serum pregnancy test will be done for subjects with a positive 
urine test. Subjects with a positive pregnancy test result at screening will be excluded 
from the trial. The frequency of pregnancy tests may be modified based on local 
regulatory requirements and pregnancy tests can be performed at any point during trial if 
pregnancy is suspected.
Any value outside the normal range will be flagged for the attention of the investigator, 
who must indicate whether or not a flagged value is of clinical significance. If [ADDRESS_1146171](s) may be repeated. If the result of any test (or repeat 
test, if done) is indicated as clinically significant in the samples taken during the 
screening period, the subject will NOT be enrolled into the trial without the permission of 
the medical monitor. In addition, follow-up unscheduled laboratory tests should be 
performed on clinically significant abnormalities. Unscheduled laboratory tests may be 
repeated at any time at the discretion of the investigator for appropriate medical care.
In addition, subjects should be excluded if they have any other abnormal laboratory test 
result at screening that, in the investigatorâ€™s judgment, is medically significant in that it 
would impact the safety of the subject or the interpretation of the trial results. However, 
any abnormal screening laboratory result(s) considered to be clinically significant should 
be repeated as soon as possible to confirm the finding(s) before excluding the subject 
from the trial. Appendix [ADDRESS_1146172]â€™s medical 
history and clinical presentation.
[IP_ADDRESS] Physical Examination and Vital Signs
[IP_ADDRESS].[ADDRESS_1146173] of measurement of height and a review of the 
following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; 
extremities; neurological; and skin and mucosae. A complete physical examination is an 
integral part of trial safety assessments and includes a urogenital assessment. A 
urogenital assessment should be performed on all trial subjects according to local medical 
standards as applied to other body systems. For the purposes of this trial, at a minimum, 
the urogenital examination should be performed within the year prior to the date of the 
ICF being signed or during the screening period for Trial 331-201-[ZIP_CODE]. The urogenital 
examination may be performed by [CONTACT_423]â€™s primary care provider or pediatrician as 
long as the source records are obtained, and the findings documented. At baseline and Clinical Study Report 331-201-[ADDRESS_1146174]. 
Height will be measured with a stadiometer, measuring stick or tape at specified visits. 
The principal investigator [INVESTIGATOR_022]/her appointed designee is primarily responsible to 
perform the physical examination. If the appointed designee is to perform the physical 
examination, he/she must be permitted by [CONTACT_35060]/her name [CONTACT_826383]. Whenever possible, the same individual 
should perform all physical examinations. Any condition present at the post-treatment 
physical examination that was not present at the baseline examination should be 
documented as an AE and followed to a satisfactory conclusion.
The following procedures will aid in the standardization of waist circumference 
measurements:
â€¢The subject should be minimally clothed (ie, lightweight clothing; no heavy 
overgarments).
â€¢Waist circumference should be recorded before a subjectâ€™s meal and at approximately 
the same time at each visit.
â€¢Measurement will be accomplished by [CONTACT_35059] a weighted measuring tape in a horizontal plane around 
the abdomen at the level of the crest. Before reading the tape measure, the assessor 
should assure that the tape is snug, but does not compress the skin, and is parallel to 
the floor. The measurement is to be made at the end of a normal exhalation.18 
[IP_ADDRESS].2 Vital Signs
Vital sign measurements will include body weight (measured at baseline, Week 14, and 
Week 26), body temperature, systolic blood pressure (SBP), diastolic blood pressure 
(DBP), and heart rate. The following guidelines will aid in the standardization of body 
weight measurements:
â€¢The same scale should be used to weigh a given subject each time, if possible.
â€¢Scales should be calibrated and reliable; scales should be at zero just prior to each 
subjectâ€™s weigh-in session.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
46
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 46 Version 6.0, 07 Jul 2022â€¢A subject should void prior to being weighed and be minimally clothed (ie, no shoes 
or heavy overgarments).
â€¢Weight should be recorded before a subjectâ€™s meal and at approximately the same 
time at each visit.
Blood pressure and heart rate measurements will be made in the supi[INVESTIGATOR_572577] [ADDRESS_1146175] any vital sign measurement at screening that, in 
the investigatorâ€™s judgment, is medically significant in that it would impact the safety of 
the subject or the interpretation of the trial results. However, any abnormal screening 
vital sign result(s) considered to be clinically significant may be repeated once to confirm 
the finding(s) before excluding the subject from the trial. Appendix [ADDRESS_1146176]â€™s medical history and clinical presentation.
[IP_ADDRESS] Electrocardiogram Assessments
All ECG recordings will be obtained after the subject has been supi[INVESTIGATOR_178664] 5 minutes. Additional ECGs may be obtained at the investigatorâ€™s discretion and 
should always be obtained in the event of an ET. A central ECG service will be utilized 
for reading all ECGs in order to standardize interpretations for the safety analysis. In 
addition, ECG results will be evaluated at the investigational site to monitor safety during 
the trial. The principal investigator [INVESTIGATOR_510974], sign, and date each 
ECG reading, noting whether or not any abnormal results are of clinical significance. The 
ECG will be repeated if any results are considered to be clinically significant.
If, according to the investigator's judgment, any abnormal ECG finding is deemed 
medically significant (impacting the safety of the subject and/or the interpretation of the 
trial results) or meets an exclusion criterion, the subject should be excluded from the trial. 
Abnormal results for ECGs should be repeated once at screening with [ADDRESS_1146177] based 
on the criteria noted above. Each ECG recording should be taken approximately Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
47
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 47 Version 6.0, 07 Jul [ZIP_CODE] minutes apart (the ECG result reported will be evaluated at each time point). The 
central ECG service will provide the corrections for the 3 ECGs performed. 
A screening ECG finding of QT interval as corrected for heart rate by [CONTACT_6550]â€™s 
formula  (QTcF) â‰¥ 450 msec for males and â‰¥ 470 msec for females based on the results 
from the central reader is exclusionary. However, any ECG with abnormal result(s) 
considered to be clinically significant should be repeated as soon as possible to confirm 
the finding(s) before excluding the subject from the trial. Appendix 3 is provided a s a 
guide for determining potentially clinically relevant ECG abnormalities. 
[IP_ADDRESS] Other Safety Assessments
It is required that a trained and experienced clinician administer the safety assessments, 
including the EPS scales (SAS, AIMS, and BARS), and C-SSRS. The number of raters 
within each trial site should be kept to a minimum. All efforts will be made to ensure that 
the same clinician administers the scales for a given subject. Training and materials for 
rating will be provided by [CONTACT_826363].
[IP_ADDRESS].[ADDRESS_1146178] of 10 symptoms of Parkinsonism (gait, arm droppi[INVESTIGATOR_007], 
shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, 
salivation, and akathisia). Each item will be rated on a 5-point scale, with a score of zero 
representing absence of symptoms, and a score of 4 representing a severe condition. The 
SAS Total Score is the sum of the scores for all 10 items. Anticholinergics, propranolol, 
benzodiazepi[INVESTIGATOR_1651], and non-benzodiazepi[INVESTIGATOR_444435] 8 hours of 
scale administration (see Section 4). Investigators are encouraged to delay scale 
administration until [ADDRESS_1146179] elapsed, if at all possible. However, if delaying 
administration of the scale is not feasible, the SAS should still be administered and the 
use of the medication documented, including a notation of the drug name, dose, and time 
of administration on the eSource.
[IP_ADDRESS].2 Abnormal Involuntary Movement Scale 
The AIMS16 assessment consists of 10 items describing symptoms of dyskinesia. Facial 
and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk 
movements (item 7) will be observed unobtrusively while the subject is at rest (eg, in the 
waiting room), and the investigator will also make global judgments on the subjectâ€™s 
dyskinesias (items 8 through 10). Each item will be rated on a 5-point scale, with a score 
of zero representing absence of symptoms (for item 10, no awareness), and a score of 4 
indicating a severe condition (for item 10, awareness, severe distress). For this scale, the Clinical Study Report 331-201-[ADDRESS_1146180], firm chair. In addition, the AIMS includes 2 yes/no 
questions that address the subjectâ€™s dental status. Anticholinergics, propranolol, 
benzodiazepi[INVESTIGATOR_1651], and non-benzodiazepi[INVESTIGATOR_444435] 8 hours of 
scale administration (see Section 4). Investigators are encouraged to delay scale 
administration until [ADDRESS_1146181] elapsed, if at all possible. However, if delaying 
administration of the scale is not feasible, the AIMS should still be administered and the 
use of the medication documented, including a notation of the drug name, dose, and time 
of administration on the eSource.
The AIMS Movement Rating Score is defined as the sum of items 1 through 7 (ie, items 
1 through 4, facial and oral movements; items 5 and 6, extremity movements; and item 7, 
trunk movements).
[IP_ADDRESS].3 Barnes Akathisia Rating Scale 
The BARS20 consists of 4 items related to akathisia: objective observation of akathisia by 
[CONTACT_093], subjective feelings of restlessness by [CONTACT_423], subjective distress due 
to akathisia, and global clinical assessment of akathisia. The first 3 items will be rated on 
a 4-point scale, with a score of zero representing absence of symptoms and a score of 3 
representing a severe condition. The global clinical evaluation will be made on a 6-point 
scale, with zero representing absence of symptoms and a score of 5 representing severe 
akathisia. To complete this scale, subjects will be observed while they are seated and then 
standing for a minimum of 2 minutes in each position. Symptoms observed in other 
situations (eg, while engaged in neutral conversation or engaged in activity on the ward) 
may also be rated. Subjective phenomena are to be elicited by [CONTACT_81257]. 
Anticholinergics, propranolol, benzodiazepi[INVESTIGATOR_1651], and non-benzodiazepi[INVESTIGATOR_444436] 8 hours of scale administration (see Section 4). Investigat ors are 
encouraged to delay scale administration until [ADDRESS_1146182] elapsed, if at all possible. 
However, if delaying administration of the scale is not feasible, the BARS should still be 
administered and the use of the medication documented, including a notation of the drug 
name, dose, and time of administration on the eSource. The BARS Global Score is 
defined as the global clinical assessment of akathisia.
[IP_ADDRESS].4 Columbia-Suicide Severity Rating Scale
Suicidality will be monitored during the trial using the C-SSRS. The â€œsince last visitâ€ 
C-SSRS will be completed for all subjects at all visits. The pediatric version will be used 
and may be completed with caregiver assistance if required (eg, if the subject is unwilling 
or unable to participate as the primary respondent). Whether the caregiver is required to 
assist will be left to investigator judgment.Clinical Study Report 331-201-[ADDRESS_1146183] at the time 
of signing the informed consent/assent of Trial 331-201-[ZIP_CODE] through the end of the 
evaluation period (defined as the time period during which subjects are evaluated for 
primary and/or secondary objectives) in the eSource. The investigator will record all 
medications and therapi[INVESTIGATOR_331637] (defined as the last date of contact [CONTACT_331664]) in the eSource.
3.7.5 Pharmacokinetic/Pharmacodynamic Assessments
[IP_ADDRESS] Pharmacokinetic Assessments 
There are no PK assessments in this trial.
3.7.[ADDRESS_1146184] completing or 
withdrawing from the trial.
3.7.7 Independent Data Monitoring Committee
This trial will be monitored by [CONTACT_23275] (DMC). The 
DMC will monitor safety based on a predetermined schedule as outlined in the DMC 
charter. The DMC meetings will occur as outlined in the DMC charter, but can be 
convened at any time at the discretion of the DMC chair or the trial medical officer. The 
details of the DMC structure and its roles and responsibilities will be documented in a 
DMC charter.
3.8 Stoppi[INVESTIGATOR_1869], Withdrawal Criteria, and Procedures
3.8.1 Entire Trial 
If the sponsor terminates or suspends the trial for any reason, prompt notification will be 
given to investigators, IRBs/IECs, and regulatory authorities in accordance with 
regulatory requirements.
3.8.2 Individual Site
Individual trial site participation may be discontinued by [CONTACT_456], the investigator, or 
the IRB/IEC if judged to be necessary for medical, safety, regulatory, ethical or other 
reasons consistent with applicable laws, regulations, and GCP. A particular trial site may Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
50
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 50 Version 6.0, 07 Jul 2022be terminated from the trial at the discretion of the investigator, sponsor, or IRB/IEC, eg, 
for non-enrollment of subjects or noncompliance with GCP or with the protocol. The 
investigator will notify the sponsor promptly if the trial is terminated by [CONTACT_826364]/IEC at the site.
3.8.[ADDRESS_1146185] Discontinuation
[IP_ADDRESS] Treatment Interruption
All attempts should be made to avoid treatment interruption during the trial. For subjects 
who have an interruption of treatment, the investigator or designee will contact [CONTACT_826365]. The investigator and medical monitor will come as 
quickly as possible to a joint decision regarding the subjectâ€™s continuation in the trial. 
This decision will be documented by [CONTACT_663563]. The 
treatment interruption will be recorded in the eSource and also recorded as a protocol 
deviation (Section 3.13).
[IP_ADDRESS] Treatment Discontinuation
After starting open-label IMP, a subject may stop treatment permanently for a variety of 
reasons. Treatment discontinuations may be initiated by a subject who is not satisfied 
with treatment or may become medically necessary due to AEs, required treatment with a 
disallowed medication or therapy, or other issues, as determined by [CONTACT_093]. 
However, each investigator must comprehensively review the circumstances and offer the 
subject options for continued treatment to the degree possible as described in 
Section [IP_ADDRESS].
If a subject discontinues from the trial prematurely, the reason must be fully evaluated 
and recorded appropriately in source documents and in eSource. If the subject is being 
withdrawn because of an AE, that AE should be indicated as the reason for withdrawal. 
All subjects have the right to withdraw at any point during treatment without prejudice. 
The investigator can discontinue a subjectâ€™s participation in the trial at any time if 
medically necessary.  
[IP_ADDRESS] Documenting Reasons for Treatment Discontinuation
A subject may discontinue IMP for a number of reasons including those listed below:
â€¢Reasons related to AE:
â€¢Subject decides to discontinue because of annoyance or discomfort due to a 
non-serious AE which is not otherwise determined to be an undue hazardClinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
51
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 51 Version 6.0, 07 Jul 2022â€¢Continuing IMP places the subject at undue risk as determined by [CONTACT_093] 
(eg, a safety concern that is possibly, probably, or likely related to IMP)
â€¢Serious adverse event (SAE) 
â€¢Clinical worsening, suicidality, and unusual changes in behavior, and the risk 
of increased suicidality
â€¢Death
â€¢Reasons unrelated to medical condition (provide detail and review AE history with 
subject)
â€¢Withdrawal of informed consent/assent (complete written withdrawal of ICF/IAF)
â€¢Lost to follow-up
â€¢Pregnancy (see Section 5.5)
â€¢Termination of all or part of the trial by [CONTACT_826366], the investigator, or other trial personnel, 
will make every effort to follow the event until it has resolved or stabilized. Follow-up 
procedures in Section 5.7 should be followed.
[IP_ADDRESS] Withdrawal of Consent
All subjects have the right to withdraw their consent/assent from further participation in 
the trial at any time without prejudice. Subjects cannot withdraw consent/assent for use of 
data already collected as part of the trial, but only for future participation. The 
investigator can also discontinue a subjectâ€™s participation in the trial at any time if 
medically necessary. Unless the subject (or their legal guardian) provides their written 
withdrawal of consent/assent or there is other written documentation by [CONTACT_826367]â€™s verbal intent to completely withdraw from the trial, subjects 
should be followed for all protocol-specified evaluations and assessments, if possible.
Complete withdrawal of consent/assent requires a subjectâ€™s refusal of ALL of the 
following methods of follow up (these methods of follow up will also be noted in the trial 
ICF):
â€¢Participation in all follow-up procedures specified in the protocol (whether in-clinic, 
by [CONTACT_756], or by [CONTACT_28920]-home visit).
â€¢Participation in a subset of protocol specified follow-up procedures (by a frequency 
schedule and method, as agreed by [CONTACT_330210]).
â€¢Contact [CONTACT_330211], even if only by [CONTACT_756], to assess current 
medical condition, and obtain necessary medical or laboratory reports relevant to the 
trialâ€™s objectives.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
52
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 52 Version 6.0, 07 Jul 2022â€¢Contact [CONTACT_308705](s) who have been designated in source records as being 
available to discuss the subjectâ€™s medical condition, even if only by [CONTACT_756], mail, 
or e-mail (eg, family, spouse, partner, legal representative, friend, neighbor, or 
physician).
â€¢Access to medical information from alternative sources (eg, hospi[INVESTIGATOR_307]/clinic medical 
records, referring doctorâ€™s notes, public records, dialysis, transplantation or vital 
registries, social media sources). 
Withdrawal of consent/assent is a critical trial event and therefore should be approached 
with the same degree of importance and care as is used in initially obtaining informed 
consent/assent. The reasons for a subjectâ€™s intended withdrawal need to be completely 
understood, documented, and managed to protect the rights of the subject and the 
integrity of the trial. A subject (or their legal guardian) may initially express their desire 
to discontinue IMP administration, which is not equivalent to a complete withdrawal of 
consent/assent for further participation (see Section [IP_ADDRESS]). A subject ma y, however, 
indicate that further trial participation is creating a burden on their work or social 
schedule. Therefore, the investigator should follow the procedures outlined in 
Section [IP_ADDRESS] to dete rmine if the subject can continue participation in the trial if 
modifications to his/her treatment and/or schedule of assessments can be accommodated. 
Only subjects (or their legal guardians) who withdraw their permission for all of the 
above degrees of follow-up are considered to have completely withdrawn their 
consent/assent to participate in the trial.
[IP_ADDRESS] Procedures to Encourage Continued Trial Participation
In all cases of impending IMP discontinuation or consent/assent withdrawal, investigators 
will be given instructions to meet and discuss with the subject their options of continuing 
in the trial, preferably on therapy. The investigator should ensure understanding and 
documentation of the reasons for the subjectâ€™s desire to withdraw consent/assent.  
3.[ADDRESS_1146186] is one from whom informed consent/assent is obtained and is 
documented in writing (ie, subject signs an ICF), but who is not started on open-label 
treatment. Rollover subjects who do not qualify for Trial 331-201-[ADDRESS_1146187] visit 
of Trial 331-201-[ZIP_CODE] may not be rescreened.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
53
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 53 Version 6.0, 07 Jul [ZIP_CODE].10 Definition of Completed Subjects
The treatment period is defined as the time period during which subjects are evaluated for 
primary and/or secondary objectives of the trial irrespective of whether or not the subject 
actually consumed all doses of the IMP. Subjects who are evaluated at the last scheduled 
visit during the treatment period will be defined as trial completers. For purposes of this 
trial, subjects who complete the Week [ADDRESS_1146188] a known reason for discontinuation (eg, withdrew consent/assent 
or AE), and for whom a survival status at the end of the trial cannot be determined will be 
classified as â€œlost to follow-upâ€ as the reason for discontinuation. Survival status can be 
determined from a variety of sources, either by [CONTACT_788495] (ie, death certificate, medical records, public records, statement by a family 
member or primary care physician) or acceptable documentation for life (ie, direct 
contact [CONTACT_1155], medical records, successful telephone contact [CONTACT_1155], 
statement by a family member or primary care physician, or public records).
The site will make [ADDRESS_1146189] via certified mail or an alternative similar method, where appropriate, before 
assigning a â€œlost to follow-upâ€ status.
3.[ADDRESS_1146190] Compliance 
Responsible trial personnel will dispense the IMP (open-label brexpi[INVESTIGATOR_4253]) to subjects. 
Accountability and compliance verification should be documented in the subjectâ€™s trial 
records. Subjects must be counseled on the importance of taking the IMP as directed at 
all trial visits. If poor compliance continues (eg, multiple missed doses resulting in less 
than 80% overall compliance), discontinuation of the subject from the trial should be 
considered.
3.13 Protocol Deviations
This trial is intended to be conducted as described in this protocol. In the event of a 
significant deviation from the protocol due to an emergency, accident, or mistake (eg, 
violation of informed consent/assent process, IMP dispensing or subject dosing error, 
treatment assignment error, subject enrolled in violation of eligibility criteria or 
concomitant medication criteria), the investigator or designee will contact [CONTACT_826368] 331-201-[ADDRESS_1146191]â€™s continuation in the trial. This 
decision will be documented by [CONTACT_31376], and reviewed by [CONTACT_162071].
[ADDRESS_1146192] agree to abstain from prohibited medications during the trial 
(Table 4.1-1). Other therapi[INVESTIGATOR_826333] i
n Section 4.2.
Table 4.1-[ADDRESS_1146193] of Medications Prohibited During the Trial
1. All psychotropic agents including, but not limited to, the following:
a) Antipsychotics, including IR IM and depot or long-acting injectable formulations
b) Symby[CONTACT_276200]
c)   Antidepressants (including monoamine oxidase inhibitors)
d) Mood stabilizers (ie, lithium or anticonvulsants)
e) Benzodiazepi[INVESTIGATOR_1651], except specific benzodiazepi[INVESTIGATOR_826334]
f) Stimulants, except when being used for treatment of ADHD.b
g) Other psychotropi[INVESTIGATOR_1102] 
2. Ramelteon and other non-benzodiazepi[INVESTIGATOR_34900], except for limited use of specific medications 
for the treatment of insomniac
3. Antihistamines (except for loratadine and cetirizine)
4. Varenicline
5. Other nutritional supplements and nonprescription herbal preparations with central nervous system 
effects (eg, St. Johnâ€™s Wort, omega-3 fatty acids, kava extracts, GABA supplements) unless 
approved in advance by [CONTACT_7195].
6. CYP2D6 inhibitors and CYP3A4 inhibitors and inducers. 
7. Investigational agents
GABA = gamma-aminobutyric acid; IM = intramuscular; IR = immediate-release.
aUse of intramuscular benzodiazepi[INVESTIGATOR_826335]. However, limited use of specific oral benzodiazepi[INVESTIGATOR_826336].
bMust be on a stable dose for â‰¥ [ADDRESS_1146194] not be changed during trial 
participation.
cNon-benzodiazepi[INVESTIGATOR_34900] (ie, clonidine, melatonin, zolpi[INVESTIGATOR_6730], zaleplon, zopi[INVESTIGATOR_11123], and 
eszopi[INVESTIGATOR_34901]) are permitted in the trial for the treatment of insomnia, but not on the same day as 
administration of a benzodiazepi[INVESTIGATOR_050], regardless of indication. For the non-benzodiazepi[INVESTIGATOR_34900], 
sites should only utilize one of the listed medications that are approved for this indication in their 
respective countries and the country-specific prescribing information is to be used to determine the 
maximum allowable daily dose for the treatment of insomnia (exceptions: clonidine, which is 
commonly prescribed off label as a sleep aid, and melatonin, which is available over the counter 
[OTC]). Non-benzodiazepi[INVESTIGATOR_826337] [ADDRESS_1146195] 
elapsed, if at all possible. However, if delaying administration of efficacy and EPS scales is not 
feasible, the scales should still be administered and the use of the sleep aid documented, including a 
notation of the drug name, dose, and time of administration on the eSource.
During the course of the trial, oral benzodiazepi[INVESTIGATOR_826338]â€™s judgment with the exceptions and 
restrictions outlined in Table 4.1-2. All concomitant medications should be prescribed 
according to the respective drug labels. Subjects who are started on therapy should be 
observed closely for clinical worsening, suicidality, and unusual changes in behavior, and 
the risk of increased suicidality must be balanced with the clinical need.
Table 4.1-2 Oral Benzodiazepi[INVESTIGATOR_826339] (mg/day)c
Lorazepama [ADDRESS_1146196] of CYP2D6 inhibitors and CYP3A4 inhibitors 
and inducers which are prohibited during the duration of the trial. Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
56
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 56 Version 6.0, 07 Jul 2022Table 4.1-3 Selected CYP2D6 Inhibitors and CYP3A4 Inhibitors and 
Inducers Prohibited During the Trial
Selected CYP2D6 Inhibitors
Celecoxib Hydroxyzine
Chloroquine Methadone
Chlorpheniramine Moclobemide
Clemastine Paroxetine
Clomipramine Pyrilamine
Diphenhydramine Quinidine
Fluoxetine Terbinafine
Halofantrine Tripelennamine
Selected CYP3A4 Inhibitors
Amiodarone Fluvoxamine
Amprenavir Indinavir
Aprepi[INVESTIGATOR_92642] (if used orally) Quinupristin/Dalfopristin 
Delavirdine Ritonavir
Diltiazem Saquinavir
Erythromycin Troleandomycin
Fluconazole Verapamil
Selected CYP3A4 Inducers
Carbamazepi[INVESTIGATOR_92644]. Johnâ€™s Wort
Oxcarbazepi[INVESTIGATOR_826340]
4.2 Other Restrictions 
Any history of electroconvulsive therapy is exclusionary.
Anticholinergics are permitted for the treatment of EPS up to a maximum of 4 mg/day 
benztropi[INVESTIGATOR_826341] (PRN), but subject 
age and body weight should be considered for dose selection. Subjects receiving a stable 
dose of propranolol for other conditions at entry into Trial 331-201-[ADDRESS_1146197]â€™s best medical interests should guide the investigator in the management of 
conditions that are pre-existing or that develop during the trial (intercurrent illness or 
AEs). The investigator should examine the acceptability of all concomitant medications 
not explicitly prohibited. In order to ensure that appropriate concomitant therapy is Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
57
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 57 Version 6.0, 07 Jul 2022administered, it is essential that subjects be instructed not to take any medications (either 
self-administered non-prescription drugs or prescription therapy prescribed by [CONTACT_3213]) without prior consultation with the investigator. All trial personnel should be 
familiar with the content of the IB for brexpi[INVESTIGATOR_788454]â€™s 
condition adequately and select appropriate concomitant medications, if needed.
4.2.1 Non-therapy Precautions and Restrictions
[IP_ADDRESS] Precautions
Subjects should not undergo any elective medical procedure without prior consultation 
with the investigator. An elective procedure (minor surgery, dental surgery, orthopedic 
surgery, etc) that might require hospi[INVESTIGATOR_826342].
[IP_ADDRESS] Restrictions
With the exception of group therapy and outpatient group therapy, new-onset 
psychotherapy is prohibited during the trial. In other words, except for inpatient and 
outpatient group therapi[INVESTIGATOR_014], subjects may continue to receive psychotherapy (eg, 
individual, group, or family therapy) if this has been ongoing throughout the double-blind 
trial period directly preceding trial entry, and if psychotherapy participation and 
frequency are maintained during the course of the trial, unless permission is obtained 
from the medical monitor.
Consumption of grapefruit, grapefruit products, Seville oranges, or Seville orange 
products within [ADDRESS_1146198] 
and unintended response to an IMP related to any dose administered.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
58
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 58 Version 6.0, 07 Jul 2022A suspected adverse reaction is any AE for which there is a reasonable possibility that the 
IMP caused the AE. For the purpose of IND safety reporting, â€œreasonable possibilityâ€ 
means there is evidence to suggest a causal relationship between the IMP and the AE. 
Suspected adverse reaction implies a lesser degree of certainty about causality.
An SAE includes any event that results in any of the following outcomes:
â€¢Death
â€¢Life-threatening; ie, the subject was, in the opi[INVESTIGATOR_871], at 
immediate risk of death from the event as it occurred. It does not include an event 
that, had it occurred in a more severe form, might have caused death.
â€¢Persistent or significant incapacity/disability or substantial disruption of the 
ability to conduct normal life functions.
â€¢Requires in-patient hospi[INVESTIGATOR_34908].
ï€­Hospi[INVESTIGATOR_444437]; whenever possible the 
reason for the hospi[INVESTIGATOR_92657].
ï€­Hospi[INVESTIGATOR_92658] (ie, those 
required for reasons of convenience or other non-medical need) are not 
considered SAEs.
â€¢Congenital anomaly/birth defect.
â€¢Other medically significant events that, based upon appropriate medical 
judgment, may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed above; eg, allergic 
bronchospasm requiring intensive treatment in an emergency room or home, 
blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse.
Nonserious adverse events are all AEs that do not meet the criteria for a "serious" AE.
Immediately Reportable Event (IRE):  
â€¢Any SAE.
â€¢Any AE related to occupational exposure.
â€¢Potential serious hepatotoxicity case (see Section 5.4). 
â€¢Pregnancies are also defined as IREs. Although normal pregnancy is not an AE, it 
will mandate IMP discontinuation and must be reported on an IRE form to the 
sponsor. Pregnancy will only be documented on the AE page of the eSource if 
there is an abnormality or complication.
Clinical Laboratory Test Value Changes: It is the investigatorâ€™s responsibility to review 
the results of all laboratory tests as they become available. This review will be Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
59
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 59 Version 6.0, 07 Jul 2022documented by [CONTACT_093]â€™s dated signature [CONTACT_444495]. For each 
abnormal laboratory test result, the investigator needs to ascertain if this is an abnormal 
(ie, clinically significant) change from baseline for that individual subject. This 
determination, however, does not necessarily need to be made the first time an abnormal 
value is observed. The investigator may repeat the laboratory test or request additional 
tests to verify the results of the original laboratory tests. If this laboratory value is 
considered medically relevant by [CONTACT_093] (subject is symptomatic, requiring 
corrective treatment or further evaluation), or if the laboratory value leads to 
discontinuation, and/or fulfills a seriousness criterion, this is considered an AE. 
Severity: Adverse events will be graded on a 3-point scale and reported as indicated in 
the eSource. The intensity of an adverse experience is defined as follows:
1 = Mild: Discomfort noticed, but no disruption to daily activity.
2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity.
3 = Severe: Inability to work or perform normal daily activity.
IMP Causality: Assessment of causal relationship of an AE to the use of the IMP is 
defined as follows:
Related: There is a reasonable possibility of a temporal and causal 
relationship between the IMP and the AE.
Not Related: There is no temporal or causal relationship between the IMP and 
the AE.
5.2 Eliciting and Reporting Adverse Events
The investigator will periodically assess subjects for the occurrence of AEs. To avoid 
bias in eliciting AEs, subjects should be asked the non-leading question: â€œHow have you 
felt since your last visit?â€ All AEs (serious and nonserious) reported by [CONTACT_826369]. Serious AE 
collection is to begin after a subject has signed the ICF.  
Use medical terminology in AE reporting. Adverse events should be reported as a single 
unifying diagnosis whenever possible or, in the absence of a unifying diagnosis, as 
individual signs or symptoms. Exacerbation or disease progression should be reported as 
an AE only if there are unusual or severe clinical features that were not present, or 
experienced earlier, or not expected based on the course of the condition. A reported AE Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
60
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 60 Version 6.0, 07 Jul 2022that undergoes a change in severity, seriousness, or toxicity should be reported as a new 
AE on the eSource.
Note: Normal pregnancy is not an AE and should not be recorded on the eSource; 
guidelines outlined in Section 5.[ADDRESS_1146199] be completed and sent by e-mail, fax, or overnight 
courier to the sponsor. (Please note that the IRE form is NOT the AE page of the 
eSource.) 
Subjects experiencing SAEs should be followed clinically until their health has returned 
to baseline status, or until all parameters have returned to normal or have otherwise been 
explained. It is expected that the investigator will provide or arrange appropriate 
supportive care for the subject and will provide prompt updates on the subjectâ€™s status to 
the sponsor.
5.[ADDRESS_1146200] who experiences an elevation in aspartate aminotransferase (AST) or 
alanine aminotransferase (ALT) that is ï‚³ 2 times the upper limit of normal (ULN), a total 
bilirubin level should also be evaluated. If the total bilirubin is ï‚³ 1.[ADDRESS_1146201], 
complete an IRE form with all values listed and also report as an AE in the eSource.
5.5 Pregnancy
Females of child-bearing potential (FOCBP) are defined as female subjects for whom 
menstruation has started and who are not documented as sterile (ie, have had a bilateral 
oophorectomy and/or hysterectomy or who have been postmenopausal for at least 
12 months).
For FOCBP and for men who are sexually active, there must be a documented agreement 
that the subject and/or their partner will take effective measures (ie, double-barrier 
method) to prevent pregnancy during the course of the trial and for [ADDRESS_1146202] be used: 
vaginal diaphragm, intrauterine device, birth control pi[INVESTIGATOR_4382], birth control implant, birth 
control depot injection, condom with spermicide, or sponge with spermicide. The 
contraceptive methods will be documented at each trial visit.
Before enrolling FOCBP in this clinical trial, investigators must review the below 
guidelines about trial participation with all FOCBP. The topi[INVESTIGATOR_78609]:
â€¢General information
â€¢Informed consent/assent form
â€¢Pregnancy prevention information
â€¢Drug interactions with hormonal contraceptives
â€¢Contraceptives in current use
â€¢Guidelines for the follow-up of a reported pregnancy
Before trial enrollment, FOCBP must be advised of the importance of avoiding 
pregnancy during trial participation and the potential risk factors for an unintentional 
pregnancy. The subject and the subjectâ€™s legally acceptable representative (eg, guardian) 
must sign an ICF/IAF stating that the above-mentioned risk factors and the consequences 
were discussed with them. 
A urine pregnancy test for human chorionic gonadotropin will be performed at screening 
on all FOCBP and female subjects â‰¥ 12 years of age and all female subjects < [ADDRESS_1146203] they might be pregnant (eg, missed or late menstrual cycle).
If a subject is suspected to be pregnant before she receives IMP, the IMP administration 
must be withheld until the results of serum pregnancy tests are available. If the pregnancy 
is confirmed, the subject must not receive the IMP and must not be enrolled in the trial. If 
pregnancy is suspected while the subject is taking IMP, the IMP must be withheld 
immediately (if reasonable, taking into consideration any potential withdrawal risks) until 
the result of the pregnancy test is known. If pregnancy is confirmed, the IMP will be 
permanently discontinued in an appropriate manner (eg, dose tapering if necessary for 
subject safety) and the subject will be withdrawn from the trial. Exceptions to trial 
discontinuation may be considered for life-threatening conditions only after consultations Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
62
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 62 Version 6.0, 07 Jul 2022with the Clinical Safety and Pharmacovigilance department (see the cover page of this 
protocol for contact [CONTACT_3031]).
The investigator must immediately notify the sponsor of any pregnancy associated with 
IMP exposure during the trial and for [ADDRESS_1146204] Pregnancy 
Surveillance Form(s) for monitoring the outcome of the pregnancy. 
Protocol-required procedures for trial discontinuation and follow-up must be performed 
on the subject unless contraindicated by [CONTACT_8663] (eg, x-ray studies). Other appropriate 
pregnancy follow-up procedures should be considered, if indicated. In addition, the 
investigator must report to the sponsor, on appropriate Pregnancy Surveillance Form(s), 
follow-up information regarding the course of the pregnancy, including perinatal and 
neonatal outcome. Infants will be followed for a minimum of 6 months from the date of 
birth.  
5.6 Procedure for Breaking the Blind 
Not applicable; this is an open-label trial.
5.7 Follow-up of Adverse Events 
For this trial, information on AEs will be followed for up to 21 (Â± 2) days after the last 
dose of IMP has been administered.
5.7.[ADDRESS_1146205] will be recorded as ongoing in the eSource. For any AE having been identified 
throughout the trial, during analysis, additional relevant medical history information may 
be requested to further ascertain causality (including, but not limited to, information such 
as risk-related behavior, family history and occupation).
5.7.2 Follow-up of Serious Adverse Events
This trial requires that subjects be actively monitored for SAEs up to 21 (Â± 2) days after 
the last dose of IMP is administered.Clinical Study Report 331-201-[ADDRESS_1146206]â€™s condition. The 
investigator will continue to report any significant follow-up information to the sponsor 
up to the point the event has been resolved.
5.7.[ADDRESS_1146207] or at any other time point after the defined 
trial period (ie, up to last scheduled contact). The investigator should follow SAEs 
identified after the last scheduled contact [INVESTIGATOR_201170], stabilized, or the 
subject is lost to follow-up. The investigator should continue to report any significant 
follow-up information to the sponsor up to the point the event has been resolved or 
stabilized.
6 Pharmacokinetic/Pharmacodynamic Analysis
Not applicable; there is no PK analysis in this trial.
7 Statistical Analysis
7.1 Sample Size
The sample size is not based on statistical considerations, but rather on the number of 
subjects rolling over from the parent trial (Trial 331-201-[ZIP_CODE]). The trial population will 
be derived from eligible subjects who completed the parent trial. The sample size of this 
open-label trial will be limited by [CONTACT_826357].
7.2 Datasets for Analysis
The following analysis samples are defined for this trial:Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
64
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 64 Version 6.0, 07 Jul 2022Enrolled Sample: All subjects who sign an ICF/IAF for the trial and are enrolled into the 
trial.Safety Sample: All subjects who receive at least 1 dose of brexpi[INVESTIGATOR_4253].
Efficacy Sample: All subjects in the Safety Sample who have a baseline assessment and 
at least one post-baseline assessment of the ABC-I subscale score.    
7.3 Handling of Missing Data
Not applicable.
7.4 Primary and Secondary Endpoint Analyses
7.4.1 Primary Endpoint Analysis
The primary objective of this trial is to evaluate safety and tolerability. The primary 
endpoints are the frequency and severity of AEs, serious TEAEs (clinical and laboratory), and discontinuation from trial due to AEs. As there is no primary efficacy objective, there is no defined primary efficacy endpoint. Descriptive statistics will be provided for all efficacy and safety variables. No inferential statistical analyses are planned for this open-label trial.
7.4.2 Secondary Endpoint Analysis
Descriptive statistics will be provided for mean change from baseline in ABC-I subscale 
score and CGI-S score. The analysis will be carried out on the Efficacy Sample. Descriptive statistics will be summarized at each trial visit using the observed cases (OC) data set and at the last visit using the last observation carried forward (LOCF) data set. Kaplan Meier curves will be used for time-to-event (eg, time to loss of effect analyses).
Further details will be provided in the statistical analysis plan (SAP).&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 65 Version 6.0, 07 Jul [ZIP_CODE].4.4 Interim Analysis
Not applicable.
7.5 Analysis of Demographic and Baseline Characteristics
Baseline demographic characteristics including age, race, ethnicity, gender, weight, 
height, and body mass index (BMI) will be summarized by [CONTACT_9086] 
(frequency, mean, median, standard deviation, maximum, minimum, and percentage 
when applicable). 
7.6 Safety Analysis
7.6.1 Adverse Events
All AEs will be coded by [CONTACT_331682] (MedDRA) preferred term. The incidence of the following events in 
Trial 331-201-[ZIP_CODE] will be summarized by [CONTACT_826370]:
â€¢Treatment-emergent AEs (TEAEs)
â€¢TEAEs by [CONTACT_926]
â€¢TEAEs potentially causally related to the IMP
â€¢TEAEs with an outcome of death
â€¢Serious TEAEs
â€¢TEAEs leading to discontinuation of the IMP 
The above summaries will also be prepared for TEAEs potentially causally related to the 
IMP.
7.6.2 Clinical Laboratory Data
The incidence of potentially clinically significant values for routine laboratory tests and 
of prolactin concentrations above the upper limit of normal will be calculated for the 
Safety Sample.
In addition to the evaluation of potentially clinically significant values, mean change 
from baseline in clinical laboratory values will be calculated. Results will be summarized 
by [CONTACT_765].
7.6.3 Physical Examination and Vital Signs Data
The incidence of potentially clinically significant vital sign abnormalities will be 
calculated. Body weight changes will be evaluated by [CONTACT_826371] 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
66
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 66 Version 6.0, 07 Jul 2022baseline and by [CONTACT_826372], 
defined as â‰¥ 7% increase or decrease from baseline. Mean changes in BMI, waist 
circumference and z-scores for height and body weight from baseline will also be 
summarized by [CONTACT_765]. Physical examination findings will be listed by [CONTACT_1130].
7.6.4 Electrocardiogram Data 
Mean change from baseline and the incidence of clinically significant changes will be 
calculated for ECG parameters for the Safety Sample.
For the analysis of QT and corrected QT interval (QTc), data from 3 consecutive 
complexes (representing 3 consecutive heart beats) will be measured to determine 
average values. The following QT corrections will be used for reporting purposes in the 
clinical study report:
1) QTcF is the length of the QT interval corrected for heart rate by [CONTACT_298901]: QTcF = QT/(RR)0.33
2) QTcN is the length of the QT interval corrected for heart rate by [CONTACT_826373]: QTcN = QT/(RR)0.37
Results will be summarized by [CONTACT_765].
7.6.5 Other Safety Data
[IP_ADDRESS] Extrapyramidal Symptoms
Descriptive statistics will be provided for the mean change from baseline to end of period 
in SAS, AIMS, and BARS scores for the Safety Sample. Results will be summarized by 
[CONTACT_826374]-baseline time-points.
[IP_ADDRESS] Suicidality
The incidence of suicidality, suicidal behavior, and suicidal ideation will be calculated 
from the potential suicide events recorded on the C-SSRS. Results will be summarized by 
[CONTACT_826375].
[ADDRESS_1146208]
For full details on IMP management, please refer to the brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE]) IB.12
8.1 Packaging and Labeling
Trial medication will be provided to the investigators and the persons designated by [CONTACT_1275](s) or institution(s) by [CONTACT_92717]. The IMP (open-label 
brexpi[INVESTIGATOR_4253]) will be supplied in child resistant blister cards. Each blister card used in Clinical Study Report 331-201-[ADDRESS_1146209] ID, compound ID, trial 
number, sponsorâ€™s name [CONTACT_3816], instructions for use, route of administration, 
appropriate precautionary statements, and other information required by [CONTACT_343505].  
8.[ADDRESS_1146210] of IMP received, 
dispensed, administered, and returned.
8.4 Returns and Destruction
The IMP will be destroyed by [CONTACT_169037]. The IMP may only be destroyed by 
[CONTACT_21655](s), if approved by [CONTACT_444464]. The IMP accountability must be completed and verified by [CONTACT_826376]. The trial site(s) may utilize qualified third party vendors for 
IMP destruction.
8.[ADDRESS_1146211] Quality Complaint (PQC) is any written, electronic, or verbal communication 
by a healthcare professional, consumer, subject, medical representative, Competent 
Authority, regulatory agency, partner, affiliate or other third party that alleges 
deficiencies or dissatisfaction related to identity, quality, labeling, packaging, reliability, 
safety, durability, tampering, counterfeiting, theft, effectiveness or performance of a drug 
product or medical device after it is released for distribution. Examples include, but are 
not limited to, communications involving:
â€¢Failure/malfunction of a product to meet any of its specifications
â€¢Incorrect or missing labelingClinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
68
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 68 Version 6.0, 07 Jul 2022â€¢Packaging issues (eg, damaged, dirty, crushed, missing product)
â€¢Blister defects (eg, missing, empty blisters)
â€¢Bottle defects (eg, under/over-fill, no safety seal)
â€¢Vial defects
â€¢Product defect (eg, odor, chipped, broken, embossing illegible)
â€¢Loss or theft of product
8.5.[ADDRESS_1146212] all PQCs identified through any means from the 
receipt of the IMP from the sponsor, or sponsorâ€™s designee, through and including 
reconciliation and up to destruction, including subject dosing. The investigator or 
designee must notify the sponsor (or sponsorâ€™s designee) by e-mail or telephone within 
24 hours of becoming aware of the PQC according to the procedure outlined below.
â€¢Online â€“ Send information required for reporting purposes (listed below) to OAPI 
[EMAIL_15723].
â€¢Telephone - Rocky Mountain Call Center at [PHONE_16438].
Identification of a PQC by [CONTACT_35084], who 
should then follow one of the reporting mechanisms above.
8.5.2 Information Required for Reporting Purposes
â€¢Description of complaint
â€¢Reporter identification (eg, subject, investigator, site, etc.)
â€¢Reporter contact [CONTACT_3031] (eg, address, phone number, e-mail address)
â€¢ID of material (product/compound name, coding)
â€¢Clinical protocol reference (number and/or trial name)
â€¢Dosage form/strength (if known)
â€¢Pi[INVESTIGATOR_499] (if available)
â€¢Availability for return
8.5.[ADDRESS_1146213] that a complaint sample for a 
dispensed kit has been forwarded to the sponsor for complaint investigation.
8.5.4 Assessment/Evaluation
Assessment and evaluation of PQCs will be handled by [CONTACT_456].
[ADDRESS_1146214] inspection by [CONTACT_92718].
Investigator(s)/institution(s) will permit trial-related monitoring, audits, IRB/IEC review, 
and regulatory inspection(s) by [CONTACT_20618]/documents by 
[CONTACT_331690]. In all cases, subject confidentiality must be 
maintained in accordance with local regulatory requirements.
9.2 Data Collection
Source document and source data will be captured electronically in this trial, and will 
meet the same fundamental elements of data quality (eg, attributable, legible, 
contemporaneous, original, and accurate) as paper records. These data will be collected 
into a system that is fully validated. Changes to the data will be captured by [CONTACT_740900].
The trial site will be given a tablet to directly record subject data and clinical 
observations on electronic forms. Designated trial site staff will not be given access to the 
system until they have been appropriately trained. Information to be originally captured 
and reviewed electronically shall include details of the subject visit and the 
protocol-required assessments performed as a part of these visits, medical history, AEs, 
and concomitant medications. Because this trial is using an electronic source record as 
the original point of data capture, there is no additional data entry step for the site for data 
collected directly into the application - rather, the electronic source record directly 
populates the trial database.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
70
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 70 Version 6.0, 07 Jul 2022Some data may be captured via paper and then entered into the eSource system. These 
and any other data treated in this manner will be source data verified by [CONTACT_826377], and the location of the source data (ie, eSource, paper, or a local 
electronic system) will be documented before the trial start. Any changes to information 
in paper source documents will be initialed and dated on the day the change is made by a 
trial site staff member authorized to make the change. Changes will be made by [CONTACT_2724] a 
single line through erroneous data (so as not to obliterate the original data), and clearly 
entering the correct data (eg, wrong data right data). If the reason for the change is not 
apparent, a brief explanation for the change will be written in the source documentation 
by [CONTACT_15370].
Another exception will be safety laboratory data, where the official source documentation 
will be considered the report issued by [CONTACT_444491].
Remote monitoring of the original electronic source record will take place, however on 
on-site monitoring inspections will continue to take place in order to review data entry 
source documentation directly captured on paper and transcribed into the system, to 
ensure protocol adherence, to assess site operational capabilities and to perform other 
monitoring activities that cannot be performed remotely.  
At the end of the trial, the investigator must certify that the data entered into the eSource 
application are complete and accurate. After database lock, the investigator will receive 
an electronic copy of the subject data. 
9.3 File Management at the Trial Site
The investigator will ensure that the trial site file is maintained in accordance with 
Section 8 of the ICH GCP Guideline E6 and as required by [CONTACT_13762]. 
The investigator/institution will take measures to prevent accidental or premature 
destruction of these documents.
9.[ADDRESS_1146215] of the following 
3 periods:
â€¢A period of at least 2 years after the date on which approval to market the drug is 
obtained (or if IMP development is discontinued, the date regulatory authorities were 
notified of discontinuation); OR
â€¢A period of at least 3 years after the sponsor notifies the investigator that the final 
report has been filed with regulatory authorities.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
71
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 71 Version 6.0, 07 Jul 2022â€¢Longer, region-specific storage requirements, if applicable.  
The investigator must not dispose of any records relevant to this trial without either 
(1) written permission from the sponsor or (2) provision of an opportunity for sponsor to 
collect such records. The investigator will be responsible to maintain adequate and 
accurate electronic or hard copy source documents of all observations and data generated 
during this trial including any data clarification forms received from the sponsor. Such 
documentation is subject to inspection by [CONTACT_331692]. 
If the investigator withdraws from the trial (eg, due to relocation or retirement), all trial-
related records should be transferred to a mutually agreed-upon designee within a 
sponsor-specified timeframe. Notice of such transfer will be given to the sponsor in 
writing.
10 Quality Control and Quality Assurance 
10.1 Monitoring
The sponsor has ethical, legal, and scientific obligations to follow this trial in accordance 
with established research principles, the ICH E6 GCP: Consolidated Guidance, and 
applicable regulatory requirements and local laws. As part of a concerted effort to fulfill 
these obligations (maintain current personal knowledge of the progress of the trial), the 
sponsor's monitors will visit the site during the trial, as well as communicate frequently 
via telephone, e-mail, and written communications. In addition, all investigators and 
clinical site personnel will undergo initial and ongoing training for this particular trial, 
and this training will be clearly documented.
10.2 Auditing
The sponsor's Quality Assurance Unit (or representative) may conduct trial site audits. 
Audits will include, but are not limited to, IMP supply, presence of required documents, 
the informed consent/assent process, and comparison of eSource with source documents. 
The investigator agrees to participate with audits.
Regulatory authorities may inspect the investigator site during or after the trial. The 
investigator will cooperate with such inspections and will contact [CONTACT_331687].Clinical Study Report 331-201-[ADDRESS_1146216] be conducted in compliance with the protocol, FDA regulations, ICH GCP 
Guideline (E6), international ethical principles derived from the Declaration of Helsinki 
and Council for International Organizations of Medical Science (CIOMS) guidelines, and 
applicable local laws and regulations. Each trial site will seek approval/favorable opi[INVESTIGATOR_826343], and the investigator will provide 
that documentation to the sponsor. The IRB/IEC will evaluate the ethical, scientific and 
medical appropriateness of the trial. Further, in preparing and handling eSource, the 
investigator, sub-investigator and their staff will take measures to ensure adequate care in 
protecting subject privacy. To this end, a subject number and subject ID code will be 
used to identify each subject.
Financial aspects, subject insurance and the publication policy for the trial will be 
documented in the agreement between the sponsor and the investigator.
12 Confidentiality
All information generated in this trial will be considered confidential and will not be 
disclosed to anyone not directly concerned with the trial without the sponsorâ€™s prior 
written permission. Subject confidentiality requirements of the region(s) where the trial is 
conducted will be met. However, authorized regulatory officials and sponsor personnel 
(or their representatives) may be allowed full access to inspect and copy the records, 
consistent with local requirements. All IMPs, subject bodily fluids, and/or other materials 
collected shall be used solely in accordance with this protocol, unless otherwise agreed to 
in writing by [CONTACT_456].
Subjects will be identified only by [CONTACT_772998]. If further subject 
ID is required, subjectsâ€™ full names may be made known to a regulatory agency or other 
authorized officials if necessary, subject to local regulations.
13 Amendment Policy
The investigator will not make any changes to this protocol without the sponsorâ€™s prior 
written consent/assent and subsequent approval/favorable opi[INVESTIGATOR_1686]/IEC. Any 
permanent change to the protocol, whether an overall change or a change for specific trial 
site(s), must be handled as a protocol amendment. Any amendment will be written by [CONTACT_826378] 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
73
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 73 Version 6.0, 07 Jul 2022sponsor. Each amendment will be submitted to the IRB/IEC, as required by [CONTACT_13125]. Except for â€œadministrativeâ€ or â€œnon-substantialâ€ amendments, investigators 
will wait for IRB/IEC approval/favorable opi[INVESTIGATOR_444443](s). Administrative amendments are defined as having no effect 
on the safety of subjects, conduct or management of the trial, trial design, or the quality 
or safety of IMP(s) used in the trial. A protocol change intended to eliminate an apparent 
immediate hazard to subjects should be implemented immediately after agreement by [CONTACT_331694], followed by [CONTACT_1744]/IEC notification within local applicable 
timelines. The sponsor will submit protocol amendments to the applicable regulatory 
agencies within local applicable timelines.
When the IRB/IEC, investigators, and/or the sponsor conclude that the protocol 
amendment substantially alters the trial design and/or increases the potential risk to the 
subject, the currently approved written ICF will require similar modification. In such 
cases, after approval/favorable opi[INVESTIGATOR_331644]/IEC, repeat written 
informed consent/assent will be obtained from subjects enrolled in the trial before 
expecting continued participation and before the amendment-specified changes in the 
trial are implemented.
[ADDRESS_1146217] of this trial 
will be based on International Committee of Medical Journal Editors (ICMJE) authorship 
criteria (http://www.icmje.org/recommendations). According to ICMJE guidelines, one 
may be considered an author only if the following criteria are met:
1. Substantial contributions to the conception or design of the work; or the 
acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved.
All authors must meet the above criteria, and all who qualify for authorship based on the 
above criteria should be listed as authors.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
74
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 74 Version 6.0, 07 Jul 2022Investigators or other trial participants who do not qualify for authorship may be 
acknowledged in publications resulting from the trial. By [CONTACT_92726], investigators or other trial participants consent/assent to such acknowledgement in 
any publications resulting from its conduct.Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
75
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 75 Version 6.0, 07 Jul 202215 References
1American Psychiatric Association: Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition. Washington, DC: American Psychiatric Association, 2013.
2Christensen DL, Baio J, Braun KVN, Bilder, D, Charles J, Constantino JN, et al. 
Prevalence and characteristics of autism spectrum disorder among children aged 8 
years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United 
States, 2012. MMWR Surveill Summ. 2016;65(No. SS-3):1-23.
3Lecavalier L. Behavioral and emotional problems in young people with pervasive 
developmental disorders: relative prevalence, effects of subject characteristics, and 
empi[INVESTIGATOR_826344]. J Autism Dev Disord. 2006;36(8):1101â€“1114.
4Samson AC, Phillips JM, Parker KJ, Shah S, Gross JJ, Hardan AY. Emotion 
dysregulation and the core features of autism spectrum disorder. J Autism Dev 
Disord. 2014;44(7):1766â€“1772.
5Autism and Developmental Disabilities Monitoring Network Surveillance Year 2000 
Principal Investigators; Centers for Disease Control and Prevention. Prevalence of 
autism spectrum disordersâ€”Autism and Developmental Disabilities Monitoring 
Network, six sites, [LOCATION_002], 2000. MMWR Surveill Summ. 2007;56(1):1â€“11.
6Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. 
Economic burden of childhood autism spectrum disorders. Pediatrics. 
2014;133(3):e520-e529.
7Elbe D, Lalani Z. Review of the Pharmacotherapy of Irritability of Autism. J Can 
Acad Child Adolesc Psychiatry. 2012;21(2):130-146.
8Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic 
medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 
2006;45(7):771-791.
9Varley CK, McClellan J. Implications of marked weight gain associated with atypi[INVESTIGATOR_826345]. JAMA. 2009;302:1811-1812.
10Fung LK, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, et al. Pharmacologic 
treatment of severe irritability and problem behaviors in autism: a systematic review 
and meta-analysis. Pediatrics. 2016;137(s2):S124-S135.
11Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. 
Cardiometabolic risk of second-generation antipsychotic medications during first-
time use in children and adolescents. JAMA. 2009;302(16):1765-1773.
12Otsuka Pharmaceutical Development & Commercialisation, Inc. Brexpi[INVESTIGATOR_4253] 
(OPC-[ZIP_CODE]) Investigatorâ€™s Brochure, Edition 17. Otsuka Report, issued 27 Sep 
2021.
13International Conference for Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use. Guideline For Good Clinical Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
76
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 76 Version 6.0, 07 Jul 2022Practice: E6(R1). Geneva, Switzerland: International Conference on Harmonisation; 
1996.
14Aman MG, Singh NN. Aberrant Behavior Checklist-Community. East Aurora, NY: 
Slosson; 1994.
15Kaat AJ, Lecavalier L, Aman MG. Validity of the aberrant behavior checklist in children with autism spectrum disorder. Journal of Autism and Developmental 
Disorders. 2014;44:1103-1116.
16Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of 
Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National 
Institute of Mental Health; 1976.
 
18The Practical Guide: Identification, evaluation, and treatment of overweight and 
obesity in adults. Developed by [CONTACT_628589], Lung 
and Blood Institute. North American Association for the Study of Obesity. NIH Publication Number 00-4084, October 2000.
19Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta 
Psychiatr Scand Suppl. 1970;212(Suppl 44):S11-19.
20Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
21Hughes HK, Kahl LK. The Johns Hopkins Hospi[INVESTIGATOR_307]: The Harriet Lane Handbook. 21st edition. 2015.
22Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in 
children and adolescents. Pediatrics. 2017;140(3).
23Soghier L, Pham K, Rooney S. Reference range values for pediatric care. The 
American Academy of Pediatrics. 2014.
24Covance. Central laboratory services manual; Protocol 331-201-[ZIP_CODE]. Created 11 Dec 2019.
25American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 
2019;42(Suppl 1):S13-S28.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
C
CI
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 77 Version 6.0, 07 Jul 2022Appendix 1 Criteria for Identifying Vital Signs Outside of Normal Values 
and of Potential Clinical Relevancea
Variable Criterion Value Change Relative to Baseline
Heart Rate at Rest21 <60 bpm or >110 bpm Increase or decrease of â‰¥ 15 bpm
Systolic Blood Pressure22
     Preschooler (5 y) <80 mmHg or >115 mmHg Increase or decrease of â‰¥ 20 mmHg
     School-age (6-9 y) <85 mmHg or >115 mmHg Increase or decrease of â‰¥ 20 mmHg
     Preadolescent (10-12 y) <90 mmHg or >120 mmHg Increase or decrease of â‰¥ 15 mmHg
     Adolescent (13-17 y) <90 mmHg or >120 mmHg Increase or decrease of â‰¥ 15 mmHg
Diastolic Blood Pressure22
     Preschooler (5 y) <45 mmHg or >80 mmHg Increase or decrease of â‰¥ 15 mmHg
     School-age (6-9 y) <50 mmHg or >80 mmHg Increase or decrease of â‰¥ 15 mmHg
     Preadolescent (10-12 y) <60 mmHg or >80 mmHg Increase or decrease of â‰¥ 15 mmHg
     Adolescent â‰¥ 13 y <60 mmHg or >85 mmHg Increase or decrease of â‰¥ [ADDRESS_1146218] meet the 
â€œCriterion Valueâ€ and also represent a change from the subjectâ€™s baseline value of at least the 
magnitude shown in the â€œChange Relative to Baselineâ€ column. When evaluating these values the 
emotional state of the subject must be taken into consideration (eg, crying, screaming) and 
documented as applicable.
Adapted information.21,22Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
78
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 78 Version 6.0, 07 Jul 2022Appendix 2 Criteria for Identifying Laboratory Values of Potential 
Clinical Relevance21,23,24,25
Laboratory TestsCriteria (Normal Ranges) for Subjects [ADDRESS_1146219] â‰¥ 2 Ã— ULN
ALT â‰¥ 2 Ã— ULN
ALP â‰¥ 2 Ã— ULN
Bicarbonate   
< 6 y < 17.0 or > 26.0 mEq/L (17.0â€“26.0 mEq/L)
6 y to 12 y < 19.0 or > 27.0 mEq/L (19.0â€“27.0 mEq/L)
â‰¥ 12 y < 19.3 or > 29.3 mEq/L (19.3â€“29.3 mEq/L)
BUN â‰¥ 24 mg/dL (â‰¤ 4 mg/dL or â‰¥ 24 mg/dL)
Creatinine
              â‰¤ 12 yâ‰¥ 0.7 mg/dL (â‰¤ 0.2 mg/dL or â‰¥ 0.7 mg/dL)
              â‰¥13 y â‰¥ 1.1 mg/dL (â‰¤ 0.3 mg/dL or â‰¥ 1.1 mg/dL)
Uric Acid
â‰¤ 12 y â‰¥ 6.7 mg/dL (â‰¤ 1.6 mg/dL or â‰¥ 6.7 mg/dL)
â‰¥ 13 y â‰¥ 8.2 mg/dL (â‰¤ 2.2 mg/dL or â‰¥ 8.2 mg/dL)
Bilirubin (total) â‰¥ 1.6 mg/dL (â‰¤ 0.2 mg/dL or â‰¥ 1.6 mg/dL)
CPK â‰¥ 2 Ã— ULN
Prolactin
                â‰¤ 12 y â‰¥ 21.00 ng/dL (â‰¤ 2.63 ng/dL or â‰¥ 21.00 ng/dL)
                â‰¥ 13 y â‰¥ 39.00 ng/dL (â‰¤ 2.52 ng/dL or â‰¥ 39.00 ng/dL)
Hematology
Hematocrit
â‰¤ 12 y â‰¤ 33 % (â‰¤ 33 % or â‰¥ 44%)
        â‰¥ 13 y â‰¤ 34 % (â‰¤ 34 % or â‰¥ 54%)
Hemoglobin
â‰¤ 12 y â‰¤11.2 g/dL (â‰¤ 11.2 g/dL or â‰¥ 15.5 g/dL)
â‰¥ 13 y â‰¤ 11.6 g/dL (â‰¤ 11.6 g/dL or â‰¥ 18.1 g/dL)
White blood count â‰¤ 4.35 Ã— 103/uL (â‰¤ 4.35 Ã— 103/uL or â‰¥ 13.65 Ã— 103/uL) 
Eosinophils
               â‰¤ 12 y â‰¥ 4.8%
               â‰¥ 13 y â‰¥ 4.1%
Neutrophils â‰¤ 40.5% (â‰¤ 40.5% or â‰¥ 75.0 %)
Absolute neutrophil count
                â‰¤ 12 y â‰¤ 1.00 Ã— 103/uL or â‰¥ 9.00 Ã— 103/uL
                â‰¥ 13 y â‰¤ 1.35 Ã— 103/uL or â‰¥ 8.15 Ã— 103/uL
Platelet count
               â‰¤ 12 y        â‰¤ 130 Ã— 103/uL (â‰¤ 130 Ã— 103/uL or â‰¥ 570 Ã— 103/uL)
               â‰¥ 13 y          â‰¤ 140 Ã— 103/uL (â‰¤ 140 Ã— 103/uL or â‰¥ 400 Ã— 103/uL)
Urinalysis
Protein Change from baseline
Glucose Presence
Additional Criteria
Chloride â‰¤ 94 mEq/L or â‰¥ 112 mEq/L
HbA1c â‰¥ 5.7%
ACTH < 7.2 pg/mL - > 63.3 pg/mL
CortisolAM: 6.7 ug/dL - 22.60 ug/dL
PM: < 10 ug/dLClinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
79
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 79 Version 6.0, 07 Jul 2022Laboratory TestsCriteria (Normal Ranges) for Subjects 5 to 17 Years of 
Age
Potassium â‰¤ 3.3 mEq/L or â‰¥ 5.2 mEq/L
Sodium â‰¤ 132 mEq/L or â‰¥ 148 mEq/L
Calcium â‰¤ 8.3 mg/dL or â‰¥ 10.9 mg/dL
Glucose
Fasting â‰¥ 100 mg/dL (â‰¥70 mg/dL and â‰¤ 100 mg/dL)
Non-Fasting â‰¥ 139 mg/dL (â‰¥ 70 mg/dL and â‰¤ 139 mg/dL)
Total Cholesterol, Fasting
                  â‰¤ 12 y â‰¥ 217 mg/dL (â‰¤ 97 mg/dL or â‰¥ 217 mg/dL)
                  â‰¥ 13 y â‰¥ 217 mg/dL (â‰¤ 124 mg/dL or â‰¥ 217 mg/dL)
LDL Cholesterol, Fasting â‰¥ 130 mg/dL 
HDL Cholesterol, Fasting
  â‰¤ 12 y â‰¤ 34 mg/dL (â‰¤ 34 mg/dL or â‰¥ 75 mg/dL)
   â‰¥ 13 y â‰¤ 30 mg/dL (â‰¤ 30 mg/dL or â‰¥ 74 mg/dL)
Triglycerides, Fasting
                  â‰¤ 12 y â‰¥ 131 mg/dL (â‰¤ 30 mg/dL or â‰¥ 131 mg/dL)
                  â‰¥ 13 y â‰¥ 148 mg/dL (â‰¤ 32 mg/dL or â‰¥ 148 mg/dL)
       TSH
                  â‰¤ 12 y â‰¤ 0.34 mIU/mL or â‰¥ 5.40 mIU/mL
                  â‰¥ 13 y â‰¤ 0.34 mIU/mL or â‰¥ 5.60 mIU/mL
       Free T4
                  â‰¤ 12 y â‰¤ 9 pmol/L or â‰¥ 30 pmol/L
                  â‰¥ 13 y â‰¤ 10 pmol/L or â‰¥ 24 pmol/L
       PT â‰¥ 12.3 sec (â‰¤ 9.7 sec or â‰¥ 12.3 sec)
       aPTT â‰¥ 29.4 sec (â‰¤ 21.9 sec or â‰¥ 29.4 sec)
       INR
                  Not taking anticoagulants
                  Taking anticoagulantsâ‰¥ 1.2 (â‰¤ 0.8 or â‰¥ 1.2)
â‰¥ 3.0 (â‰¤ 2.0 or â‰¥ 3.0)
The recommended criteria represented in this table are intended to identify on-treatment outside of normal 
values that could potentially be clinically relevant. Variations based on local laboratory ranges may need to 
be considered.
Adapted information.21,23,24,25Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
80
Protocol 331-201-[ZIP_CODE]
 Confidential - Proprietary Information 80 Version 6.0, 07 Jul 2022Appendix 3 Criteria for Identifying ECG Measurements of Potential 
Clinical Relevance
Variable Criterion ValueaChange Relative to Baselinea
Rhythm
Sinus tachycardiab â‰¥ 110 bpm increase of â‰¥ 15 bpm
Sinus bradycardiac â‰¤ 60 bpm decrease of â‰¥ 15 bpm
Supraventricular premature beat all not present ïƒ  present
Ventricular premature beat all not present ïƒ  present
Supraventricular tachycardia all not present ïƒ  present
Ventricular tachycardia all not present ïƒ  present
Atrial fibrillation all not present ïƒ  present
Atrial flutter all not present ïƒ  present
Conduction
1Â° atrioventricular block PR â‰¥ 200 msec increase of â‰¥ 50 msec
2Â° atrioventricular block all not present ïƒ  present
3Â° atrioventricular block all not present ïƒ  present
Left bundle-branch block all not present ïƒ  present
Right bundle-branch block all not present ïƒ  present
Pre-excitation syndrome all not present ïƒ  present
Other intraventricular conduction 
blockd QRS â‰¥ 120 msec increase of â‰¥ 20 msec
Infarction
Acute or subacute all not present ïƒ  present
Old all not present ïƒ  present
â‰¥ [ADDRESS_1146220]/T Morphological
Myocardial Ischemia all not present ïƒ  present
Symmetrical T-wave inversion all not present ïƒ  present
Increase in QTc QTcF â‰¥ 450 msec for 
males, â‰¥ [ADDRESS_1146221] meet the â€œCriterion 
Valueâ€ and also represent a change from the subjectâ€™s baseline value of at least the magnitude shown 
in the â€œChange Relative to Baselineâ€ column. When evaluating these values the emotional state of the 
subject must be taken into consideration (eg, crying, screaming) and documented as applicable.
bNo current diagnosis of supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial 
flutter, or other rhythm abnormality.
cNo current diagnosis of atrial fibrillation, atrial flutter, or other rhythm abnormality.
dNo current diagnosis of left bundle branch block or right bundle branch block. Clinical Study Report 331-201-[ADDRESS_1146222]:
There is no additional risk to the subjects.Clinical Study Report 331-201-[ADDRESS_1146223] read and understand the protocol (including the 
Investigator's Brochure) and agree that it contains all the ethical, legal and scientific information 
necessary to conduct this trial in accordance with the principles of Good Clinical Practices and as 
described herein and in the sponsor's (or designee's) Clinical Trial Agreement.
I will provide copi[INVESTIGATOR_35008], nurses, and other professional personnel to 
whom I delegate trial responsibilities. I will discuss the protocol with them to ensure that they are 
sufficiently informed regarding the investigational new drug, brexpi[INVESTIGATOR_4253] (OPC-[ZIP_CODE]), the 
concurrent medications, the efficacy and safety parameters and the conduct of the trial in general. 
I am aware that this protocol must be approved by [CONTACT_4707] (IRB) or receive 
a favorable opi[INVESTIGATOR_572581] (IEC) responsible for such matters in 
the clinical trial facility where brexpi[INVESTIGATOR_826346]. I 
agree to adhere strictly to the attached protocol (unless amended in the manner set forth in the 
sponsor's Clinical Trial Agreement, at which time I agree to adhere strictly to the protocol as 
amended).
I understand that this IRB- or IEC-approved protocol will be submitted to the appropriate 
regulatory authority/ies by [CONTACT_456]. I agree that clinical data entered on case report forms by 
[CONTACT_444493], such as for submission to 
governmental regulatory authorities and/or in combination with clinical data gathered from other 
research sites, whenever applicable. I agree to allow sponsor and designee monitors and 
auditors full access to all medical records at the research facility for subjects screened or enrolled 
in the trial.
I agree to await IRB/IEC approval before implementation of any substantial amendments to this 
protocol. If, however, there is an immediate hazard to subjects, I will implement the amendment 
immediately, and provide the information to the IRB/IEC within the required local applicable 
timelines. Administrative changes to the protocol will be transmitted to the IRB/IEC for 
informational purposes only, if required by [CONTACT_427].
I agree to provide all subjects with informed consent/assent forms, as required by [CONTACT_35212]. I agree to report to the sponsor any adverse experiences in 
accordance with the terms of the sponsor's Clinical Trial Agreement and the relevant regional 
regulation(s) and guideline(s). I further agree to provide all required information regarding 
financial certification or disclosure to the sponsor for all investigators and sub-investigators in 
accordance with the terms of the relevant regional regulation(s). I understand that participation in 
the protocol involves a commitment to publish the data from this trial in a cooperative publication 
before publication of efficacy and safety results on an individual basis may occur, and I consent to 
be acknowledged in any such cooperative publications that result.
____________________________ _____________________________ ___________
Principal Investigator [INVESTIGATOR_92673] 331-201-[ADDRESS_1146224] ati o n of a n el e ctr o ni c all y c a pt ur e d si g n at ur e 
SI G N A T U R E P A G E 
D o c u m e nt N a m e: Pr ot o c ol 3 3 1- 2 0 1- 0 0 1 9 1 A m e n d m e nt 5 
D o c u m e nt N u m b er: 
D o c u m e nt V er si o n: 8. 0 
Si g n e d b y M e a ni n g of Si g n at ur e S er v er D at e 
( d d- M M M- 
y y y y h h: mi n) - 
U T C ti m e z o n e 
Cli ni c al A p pr o v al 0 7- J ul- 2 0 2 2 
1 7: 5 1: [ADDRESS_1146225] ati sti c s A p pr o v al 0 7- J ul- 2 0 2 2 
2 2: 0 5: 3 1 
Cli ni c al A p pr o v al 0 7- J ul- 2 0 2 2 
1 8: 1 5: [ADDRESS_1146226] u d y Re p ort 3 3 1- 2 0 1- 0 0 1 9 1 1 6. 1. 1 Pr ot oc ol a n d Pr ot oc ol A me n d me nts 
U ntil t he i nf or m ati o n herei n is rele ase d b y Ots u k a t o t he p u blic d o m ai n, t he c o nte nts of t his d oc u me nt are Ots u k a 
c o nfi de nti al i nf or m ati o n a n d s h o ul d n ot be d u plic ate d or re- distri b ute d wit h o ut pri or writte n c o nse nt of Ots u k a. 
9 5 C CI 
P P D 
P P D 
P P D 
1
Confidential -Proprietary Information Version 1.0, 06Jul2020Otsuka Pharmaceutical Development & Commercialization, I nc
Investigational Medicinal Product
Brexpi[INVESTIGATOR_4253] (OPC -[ZIP_CODE])
ADDENDUM FOR CLINICAL PROTOCOL FOR TRIAL 331-201- [ZIP_CODE]
Protocol 331-201- [ZIP_CODE]: A Phase 3, Multicenter, Open -label Trial to Evaluate the 
Long -term Safet y and Tolerability  of Brexpi[INVESTIGATOR_4253] (OPC- [ZIP_CODE]) in the Treatment of 
Children and Adolescents with I rritability  Associated with Autism Spectrum Disorder
Protocol No. 331-201- [ADDRESS_1146227] No. 2018- 004899 -35
CONFIDENTIAL â€“PROPRI ETARY INFORMATION
Clinical Development Phase: 3
Sponsor: Otsuka Pharmaceutical Development & 
Commercialization, I nc
[ADDRESS_1146228]
Rockville, Mary land [ZIP_CODE]
Immediately Reportable Event [EMAIL_15722]
Issue Date: 06Jul2020
Version No.: 1.0Clinical Study Report 331-201-[ADDRESS_1146229] .................................................... 20
6 Prohibited Medications (Delayed Rollover Subjects From 
Trial 331-201- [ZIP_CODE]) ........................................................................... 20Clinical Study Report 331-201-[ADDRESS_1146230]
ACTH Adrenocorticotropic hormoneADHD Attention-deficit/hyperactivity disorderAE Adverse eventAIMS Abnormal Involuntary Movement ScaleBARS Barnes Akathisia Rating ScaleBP Blood pressureCGI-S Clinical Global Impression - SeverityCPK Creatine phosphokinaseCRO Clinical research organizationC-SSRS Columbia-Suicide Severity Rating ScaleCYP Cytochrome P450ECG ElectrocardiogrameCRF Electronic case report formEOT End of treatmentEPS Extrapyramidal symptomsET Early terminationFOCBP Females of child bearing potentialHbA1c Glycosylated hemoglobinIMP Investigational medicinal product
QTcB QT interval corrected for heart rate by [CONTACT_35019]'s formula
QTcF QT interval corrected for heart rate by [CONTACT_6550]'s formulaSAE Serious adverse eventSAS Simpson Angus ScaleTSH Thyroid-stimulating hormone&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
[ADDRESS_1146231] Trial Design Schematic -Subjects Who Rollover Directly From Trial 331-201- [ZIP_CODE]
Note: In order to be eligible for this trial , the baseline visit must be in office per the protocol. Eligible subjects are those subjects who complete 
Trial 331-201-[ZIP_CODE]. Subjects who w ere not able to rollover directly into this trial (Trial 331-201-[ZIP_CODE] )or are terminated early from Trial 331-201- [ADDRESS_1146232] an opportunity to enter this trial upon completion of in office screening and baseline visitsas detailed in 
Figure 1.1-
2.
Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
102
8
Confidential -Proprietary Information Version 1.0, 06Jul2020Figure 1.1-2 Trial Design Schematic -Delayed Rollover Subjects From Trial 331-201-[ZIP_CODE]
Note: In order to eligible for this trial , the screening and baseline visitsmust be in office.Treatment Period (26 weeks ) Follo w-up
Follow -up
21 (Â± 2 days)
after last
dose
of
brexpi[INVESTIGATOR_826347]
(Day  âˆ’28 to âˆ’1)
End of
treatment/
Week 26
visitVisits at Weeks 1, 2, 3, 4, 8, 14, 18, and 22Open -label brexpi[INVESTIGATOR_4253] 0.25 to 3 mg/daySubjects who were not able to 
rollover directly or are 
terminated early from 
Trial 331-201-[ZIP_CODE] due to the 
COVID -19 pandemic and who 
could potentially benefit from 
treatment with brexpi[INVESTIGATOR_826348] 1
(Baseline)
Entry into 
treatment 
periodClinical Study Report 331-201-[ADDRESS_1146233] Schedule of Assessments - Subjects Who Rollover Directly From Trial 331-201-[ZIP_CODE]
AssessmentScreening/ 
Baseline
Last visit 
from Trial 
331-201-
[ZIP_CODE]/ 
Baseline 
for Trial 
331-201-
[ZIP_CODE]
In officea26-week Open-label Treatment Period EOTFollow-
up
Week 
1
(Day 7 
Â± 2 
days)
VirtualWeek 
2
(Day 14 
Â± 2 
days)
VirtualWeek 
3
(Day 21 
Â± 2 
days)
VirtualWeek 
4
(Day 28 
Â± 2 
days)
VirtualWeek 
8
(Day 56 
Â± 2 
days)
VirtualWeek 
14
(Day 98 
Â± 2 
days)
VirtualWeek 
18 
(Day 
126 Â± 2 
days)
VirtualWeek 
22 
(Day 
154 Â± 
2 
days)
VirtualWeek 
26/ 
ET
(Day 
182 Â± 
2 
days)
In 
office21 (Â± 2) 
days 
after 
last 
dose of 
IMP
By [CONTACT_48432]-
phoneNotes
Informed 
consent/assent, 
update medical history, as neededX
Prior medications X
Inclusion/exclusion 
criteriaX
C G I - S X XXXXXXX X X
SAS, AIMS, & 
BARSXX
(AIMS 
and 
BARS)X
(AIMS 
and 
BARS)X Section 4.1.3
C - S S R S  X XXXXXXX X X
A B C X XXXXXXX X X
Physical 
examinationX X
&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
Sectio n4.1.[ADDRESS_1146234] Schedule of Assessments - Subjects Who Rollover Directly From Trial 331 - 201-[ZIP_CODE]
AssessmentScreening/ 
Baseline
Last visit 
from  Trial 
331-201-
[ZIP_CODE]/ 
Baseline 
for Trial 
331-201-
[ZIP_CODE]
In officea26-week Open -label Treatment Period EOTFollow -
up
Week 
1
(Day 7 
Â± 2 
days)
VirtualWeek 
2
(Day 14 
Â± 2 
days)
VirtualWeek 
3
(Day 21 
Â± 2 
days)
VirtualWeek 
4
(Day 28 
Â± 2 
days)
VirtualWeek 
8
(Day 56 
Â± 2 
days)
VirtualWeek 
14
(Day 98 
Â± 2 
days)
VirtualWeek 
18 
(Day 
126 Â± 2 
days)
VirtualWeek 
22 
(Day 
154 Â± 
2 
days)
VirtualWeek 
26/ 
ET
(Day 
182 Â± 
2 
days)
In 
office21 (Â± 2) 
days 
after 
last 
dose of 
IMP
By [CONTACT_48432] -
phoneNotes
Body  weight and 
waist 
circumferenceX X X Section 4.1.1
Height X X X
Vital signs X X X X X X X X X X
ECG X X
Clinical laboratory 
tests (hematology, 
serum chemistry, 
and urinalysis)X X
HbA1c X X
Prolactin X X
Urine pregnancy 
testX X X Section 4.1.[ADDRESS_1146235] Schedule of Assessments - Subjects Who Rollover Directly From Trial 331-201-[ZIP_CODE]
AssessmentScreening/ 
Baseline
Last visit 
from Trial 
331-201-
[ZIP_CODE]/ 
Baseline 
for Trial 
331-201-
[ZIP_CODE]
In officea26-week Open-label Treatment Period EOTFollow-
up
Week 
1
(Day 7 
Â± 2 
days)
VirtualWeek 
2
(Day 14 
Â± 2 
days)
VirtualWeek 
3
(Day 21 
Â± 2 
days)
VirtualWeek 
4
(Day 28 
Â± 2 
days)
VirtualWeek 
8
(Day 56 
Â± 2 
days)
VirtualWeek 
14
(Day 98 
Â± 2 
days)
VirtualWeek 
18 
(Day 
126 Â± 2 
days)
VirtualWeek 
22 
(Day 
154 Â± 
2 
days)
VirtualWeek 
26/ 
ET
(Day 
182 Â± 
2 
days)
In 
office21 (Â± 2) 
days 
after 
last 
dose of 
IMP
By [CONTACT_48432]-
phoneNotes
A d v e r s e  e v e n t s X XXXXXXX X X X
Concomitant 
medicationsX XXXXXXX X X X
D i s p e n s e  I M P X XXXXXXX X
IMP accountability X XXXXXXX X X
ABC = Aberrant Behavior Checklist; ACTH = Adrenocorticotropic hormone; AIMS =Abnormal Involuntary Movement Scale; BARS = Barnes  Akathisia 
Rating Scale; BP = blood pressure; CGI-S = Clinical Global Impression - Severity of Illness scale; C-SSRS = Columbia-Suicide Sever ity Rating Scale; 
ECG = electrocardiogram; EOT = end of treatment; ET = early termination; HbA1c = glycosylated hemoglobin; IMP = investigational me dicinal product; 
; ; SAS = Simpson-Angus Scale; TSH = thyroid-stimulating hormone.
Note: If efficacy or safety assessments cannot be obtained at consecutive virtual visits, the investigator should discuss possi ble discontinuation of the subject 
with the medical monitor. 
aIn order to eligible for this trial, the baseline visit must be in office per the protocol. Eligible subjects are those subjects  who complete Trial 331-201-[ZIP_CODE]. 
Subjects who were not able to rollover directly into this trial (Trial 331-201-[ZIP_CODE]) or are terminated early from Trial 331-201-[ADDRESS_1146236] an opportunity to enter this trial upon completion of in office screening and baseline visits as detailed in Table 1.2-2 .&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
Table1.2-2CCI CCI
Protocol 331-201-[ADDRESS_1146237] Schedule of Assessments - Delayed Rollover Subjects From Trial 331-201-[ZIP_CODE]
AssessmentScreening
(Day âˆ’28 
to âˆ’1)
In
officea26-week Open-label Treatment PeriodEOTFollow-
up
Base
line
(Day 1)
In 
officeWeek 
1
(Day 7 
Â± 2 
days)
VirtualWeek 
2
(Day 
14 Â± 2 
days)
VirtualWeek 
3
(Day 
21 Â± 2 
days)
VirtualWeek 
4
(Day 
28 Â± 2 
days)
VirtualWeek 
8
(Day 
56 Â± 2 
days)
VirtualWeek 
14
(Day 
98 Â± 2 
days)
VirtualWeek 
18 
(Day 
126 Â± 
2 
days)
VirtualWeek 
22 
(Day 
154 Â± 
2 
days)
VirtualWeek 
26/ 
ET
(Day
182 Â± 
2 
days)
In 
office21 (Â± 2) 
days 
after 
last 
dose of 
IMP
By [CONTACT_48432]-
phoneNotes
Informed 
consent/assentX
Inclusion/exclusion 
criteriaXX
Medical history X
Psychiatric history X
Verification of 
stability of comorbid 
conditionsbX
Prior medications 
and washout, if 
applicableX
C G I - S X XXXXXXXXX X
SAS, AIMS, & 
BARSXX
(AIMS 
and 
BARS)X
(AIMS 
and 
BARS)X
C - S S R S  X XXXXXXXXX X
A B C X XXXXXXXXX X
&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331-201-[ADDRESS_1146238] Schedule of Assessments - Delayed Rollover Subjects From Trial 331-201-[ZIP_CODE]
AssessmentScreening
(Day âˆ’28 
to âˆ’1)
In
officea26-week Open-label Treatment PeriodEOTFollow-
up
Base
line
(Day 1)
In 
officeWeek 
1
(Day 7 
Â± 2 
days)
VirtualWeek 
2
(Day 
14 Â± 2 
days)
VirtualWeek 
3
(Day 
21 Â± 2 
days)
VirtualWeek 
4
(Day 
28 Â± 2 
days)
VirtualWeek 
8
(Day 
56 Â± 2 
days)
VirtualWeek 
14
(Day 
98 Â± 2 
days)
VirtualWeek 
18 
(Day 
126 Â± 
2 
days)
VirtualWeek 
22 
(Day 
154 Â± 
2 
days)
VirtualWeek 
26/ 
ET
(Day
182 Â± 
2 
days)
In 
office21 (Â± 2) 
days 
after 
last 
dose of 
IMP
By [CONTACT_48432]-
phoneNotes
Physical 
examinationX X
Body weight and 
waist 
circumferenceXX X X
Height X X X
V i t a l  s i g n s  X XXXXXXXXX X
ECGXcXd X
Clinical laboratory 
tests (hematology, serum chemistry, 
and urinalysis)XcXd X
HbA1c X X
Prolactin X X
Urine drug screen X
Blood alcohol test X
Urine pregnancy 
testXX X
ACTH X X
Cortisol X X
&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol [ADDRESS_1146239] Schedule of Assessments - Delayed Rollover Subjects From Trial 331-201- [ZIP_CODE]
AssessmentScreening
(Day âˆ’28 
to âˆ’1)
In
officea26-week Open -label Treatment PeriodEOTFollow -
up
Base
line
(Day 1)
In 
officeWeek 
1
(Day 7 
Â± 2 
days)
VirtualWeek 
2
(Day 
14 Â± 2 
days)
VirtualWeek 
3
(Day 
21 Â± 2 
days)
VirtualWeek 
4
(Day 
28 Â± 2 
days)
VirtualWeek 
8
(Day 
56 Â± 2 
days)
VirtualWeek 
14
(Day 
98 Â± 2 
days)
VirtualWeek 
18 
(Day 
126 Â± 
2 
days)
VirtualWeek 
22 
(Day 
154 Â± 
2 
days)
VirtualWeek 
26/ 
ET
(Day
182 Â± 
2 
days)
In 
office21 (Â± 2) 
days 
after 
last 
dose of 
IMP
By [CONTACT_48432] -
phoneNotes
TSH with reflex to 
free T 4if abnormalX X
Coagulation 
parametersX X
Adverse events X X X X X X X X X X X X
Concomitant 
medicationsX X X X X X X X X X X X
Dispense IMP X X X X X X X X X
IMP accountability X X X X X X X X X
Note: If efficacy or safety assessments cannot be obtained at consecutive virtual visits, the investigator should discuss possible discontinuation of the su bject 
with the medical monitor.
In order to eligible for this trial, the screening and baseline visitsmust be in office. All other visits of the open -label treatment period after the baseline visit
can be virtual or performed per the protocol.
aDelayed rollover subjects must agree to discontinue all prohibited medications during the screening period as summarized in Table 6-1.
bThe investigator should verifiy the stability of comorbid conditions and that there is no potential ne w diagnosi s since the screening v ist in 
Trial 331-201-[ZIP_CODE].
cThe screening period may be extended in order to repeat clinical laboratory tests and ECGs; if an extension is required, the site should contact [CONTACT_35011].
dBaseline clinical laboratory  tests (h ematology, serum chemistry, and urinaly sis) and ECGs are not collected if screening clinical laboratory  tests/ECGs were obtained 
within [ADDRESS_1146240] the clinical research organization ( CRO )andsponsor with questions .
2.[ADDRESS_1146241] be 
recorded in eSource separat ely from other protocol deviations as soon as they  are 
identified and will be recorded as â€œMajorâ€ in eSource for data capture purposes . 
Examples of the ty pes of COVID
-19 related deviations to be reported may include: 
missed visits, missed assessments, asse ssments performed remotel y (completed outside 
of protocol procedure), missed 
investigational medicinal product ( IMP)dose, IMP 
dispensed/returned via courier, IMP not returned to site/site unable to verify medication 
compliance, out of window visits , chang es in rater, and prohibited concomitant 
medication. A â€œdirect resultâ€ isdefined as being due to actual illness, or as a result of 
quarantine, social distancing, or site closures. All other deviations will follow the normal 
deviation process described in t he protocol and should not be entered proactively  by [CONTACT_21127].
2.[ADDRESS_1146242] may  
continue in the trial with virtual visits only at the discretion of the investigator as long as 
they remain as ymptomatic for COVID -19, but an adverse event ( AE)of â€œCoronavirus 
Infectionâ€ OR â€œCorona virus Positive Test Resultâ€ must be recorded on the AE page of 
the electronic case report form ( eCRF ). All subjects who have mild sy mptoms of 
COVID -[ADDRESS_1146243] 
is not automatically  a serious advers e event (SAE ), unle ss an SAE criterion is met 
(eg,hospi[INVESTIGATOR_059]). If the event meets the criterion for an SAE, then the subject will be 
discontinued from the trial
.Clinical Study Report 331-201-[ADDRESS_1146244] tests positive OR is
presumed positive with COVID-19, then the primary reason for discontinuation should be 
reported as â€œAdverse Eventâ€ and indicate the AE number in the â€œSpecify the reason for discontinuationâ€ space that corresponds with the AE of â€œCoronavirus Infectionâ€ OR
â€œCoronavirus Positive Test Result.â€ Be sure to remember to enter an AE in the AE form 
for the â€œCoronavirus Infectionâ€ OR â€œCoronavirus Positive Test Result.â€
If a subject discontinues due to COVID-[ADDRESS_1146245] testing positive OR 
being presumed positive with COVID-19, then the primary reason for discontinuation 
should be reported as â€œOther.â€ Be sure to specify the reason as â€œCOVID-19â€ followed by
[CONTACT_826379] â€œCOVID-19.â€ Do note that the reason â€œOtherâ€ should be selected even if the subject decides to withdraw consent or if the investigator decides to withdraw the subject due to COVID-[ADDRESS_1146246] and across all subjects in the trial. Assessments 
should be administered by [CONTACT_826380]/trained rater who rated the subject 
previously; if this is not possible due to staff availability and/or technological limitations, 
discuss relevant information with previous raters to obtain clinical context (note that per 
protocol raters must be trained/qualified to conduct assessments in all cases). Raters 
should conduct all assessments for that visit during the same remote session, where 
possible.
Please refer to Study Operations Manual for modification of administration methods for 
virtual visits.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol 331 -201-[ZIP_CODE]
17
Confidential -Proprietary Information Version 1.0, 06Jul20203 Trial Population
3.1 Inclusion Criteria
There are no changes to the inclusion criteria due to COVID -19 for purposes of this 
addendum. For 
delay edrollover subjects, inclusion criteria can be found in Section 3.4.2 
of the protocol.
3.2 Exclusion Criteria
There are no changes to exclusion criteria for subjects who rol lover directly  from 
Trial 331-201-[ZIP_CODE].
Delay ed rollover subjects (ie, those who were un able to directly  rollover from 
Trial 331-201- [ZIP_CODE] due to theCOVID 19 pandemic or who were terminated earl y due 
to the COVID -19pandemic ) will be excluded if they  meet any  of the exclusion criteria 
presented in Table 3.2-1.
Table 3.2-[ADDRESS_1146247] be used: vagin al diaphragm, 
intrauterine device, birth control pi[INVESTIGATOR_4382], birth control implant, birth control depot injection, condom 
with spermicide, or sponge with spermicide. 
2. Fem ales who are breast -feeding and/or who have a positive pregnancy test result prior to 
receiving IMP.
3. Subjects who have a significant risk of committing violent acts, serious self -harm, or suicide 
based on history or routine psychiatric status examination, or those who are homicidal or 
considered to be a high risk to others, or subjects with an answer of â€œyesâ€ on C -SSRS Suicidal 
Ideation Item 4 (Active Suicidal Ideation w ith Some Intent to Act, Without Specific Plan) at 
entry or within the past three months, OR Subjects w ith a response of â€œyesâ€ on the C -SSRS 
Suicidal Ideation Item 5 (Acti ve Suicidal Ideation with Specific Plan and Intent) at entry or 
within the past three months, OR Subjects w ith a response of â€œyesâ€ on any of the 5 C -SSRS 
Suicidal Behavior Items(actual attempt, interrupted attempt, aborted attempt, preparatory acts, or 
behavior) at entry or within the past year.
4. Non-pharm acological therapy (eg, psychotherapy, behavior mod ification) is not stable for 
30days prior to screening and is not likely to be consistent throughout the trial.
5. Subjects with Type I or Type II diabetes are excluded if all of the following criteria are not met:
ï‚·HbA1c â‰¤ 6.5%,
ï‚·Screening fasting glucose is â‰¥70 mg/dL and â‰¤ 100 mg/dL or nonfasting glucose is 
â‰¥70mg/d L and â‰¤ 139 mg/dL. If the nonfasting glucose is â‰¥139 mg/dL, subjects must be 
retest ed in the fasting state. At retest, fasting glucose must be â‰¤ 100 mg/dL
ï‚·Subject has been maintained on a stable regimen of non-insulin medication(s) for at least 
28days prior to screening or diabetes has been well -controlled by [CONTACT_772982] 28 days 
prior to screening,
ï‚·Subject has not had any hospi[INVESTIGATOR_34867] 12 months prior to screening due to 
diabetes or complications related to diabetes, AND
ï‚·Subjectâ€™s diabetes is not newly diagnosed during screening for the trial.
Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
112
Protocol 331 -201-[ZIP_CODE]
18
Confidential -Proprietary Information Version 1.0, 06Jul2020Table 3.2-1 Exclusion Criteria for Delayed Rollover Subjects From 
Trial 331-201-[ZIP_CODE]
6. Subjects with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension 
which is defined as a decrease of â‰¥15 mmHg in SBP or a decrease of â‰¥15mmHg in DBP after 
at least 3 minutes standing compared to the previous supi[INVESTIGATOR_826349], ORdevelopment of 
symptoms.
7. Subjects â‰¥ [ADDRESS_1146248] is a result of 
prescription medicine(s). When a subject tests positive for cannabinoids (tetrahydrocanna binol) 
at screening, the investigator is required to evaluate the subject's ability to abstain from using this 
substance during the trial and to discuss his/her evaluation with the Medical Monitor prior to 
randomization.
8. The follow ing laboratory test and ECG results are exclusionary:
1)Platelets â‰¤ 130 Ã— 103/uL for â‰¤ 12 years of age, â‰¤ 140 Ã— 103/uL for â‰¥ 13 years of age
2)Hem oglobin â‰¤ 11.2 g/dL for â‰¤ 12 years of age, â‰¤ 11.6 g/dL for â‰¥ 13 years of age
3)Neutrophils, absolute â‰¤ 1.00 Ã— 103/uL for â‰¤ 12 years of age, â‰¤ 1.35 Ã— 103/uL for â‰¥ 13 years 
of age
4)AST â‰¥2 Ã— upper limit of normal
5)ALT â‰¥ 2 Ã— upper limit of normal
6)Creatinine â‰¥ 0.7 mg/dL for â‰¤ 12 years of age, â‰¥ 1.1 mg/dL for â‰¥ 13 years of age
7)HbA1c â‰¥6.5%
8)CPK â‰¥ 2 Ã— upper limit of normal
9)QTcF â‰¥450 msec for male s and â‰¥[ADDRESS_1146249] w eighs < [ADDRESS_1146250] who, in the opi[INVESTIGATOR_871], should not participate in the trial.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase ; 
C-SSRS  = Columbia -Suicide Severity Rating Scale ; FOCBP = females of childbearing potential; 
HbA1C = Glycosylated hemoglobin ; QTcB = QT interval corrected for heart rate by [CONTACT_35019]'s formula; 
QTcF =QT interval corrected for heart rate by [CONTACT_6550]'s formula.
[ADDRESS_1146251] circumference will be measured as described in the protocol at the 
virtual visits defined in this COVI D-19 Adden dum Schedule sof Assessments 
(Table 1.2-1 and Table 1.2- 2) with the following changes: Clinical Study Report 331-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
113
Protocol 331 -201-[ZIP_CODE]
19
Confidential -Proprietary Information Version 1.0, 06Jul2020ï‚·Caregivers 
will be asked to use an y weight collection device they currently  own
regardles sof calibration or validation, for weight measurements . (If there is no home 
weight collection device, the site will provide or reimburse for equipment. );
ï‚·Weight and waist circumference measurement does not need to be videotaped. The 
caregiver will be instructed to provide the weight and waist circumference
measurement result to site staff on the visit day .Subjects will be instructed to be as 
consistent as possible regarding the time of day  the measurement saretaken, and to 
notify  the site staff of the measurement results via telephone, or other means, on the 
appropriate visits.
ï‚·Site staff will be instructed to record the weight and waist circumference 
measurement sin eSource, and if there are believed to be any  errors, inconsistencies, 
or safet y concerns with the reported home measurement, the medical monitor should 
be notified.
4.1.2 Pregnancy
Pregnancy  tests will be performed as described in the protocol a t the virtual visits defined 
in this COVI D-19 Addendum Schedule sof Assessments ( Table 1.2-1 and Table 1.2-2) 
with the following changes: 
ï‚·For planned visits that require a pregnancy  test for females of childbearing potential
(FOCBP) , the site will provide the necessary  tests and instructions so the test may  be 
performed at home;
ï‚·Appli cable subjects will perform a pregnancy  test prior to dosing with IMP, ensuring 
a date and time -stamped pi[INVESTIGATOR_826350]
. The caregiver is to 
provide/show the result during the virtual visit .
ï€­If negative, site to inform thesubject to proceed with dosing .
ï€­If positive, the site must instruct the subject to immediately  stop taking IMP, and 
the site will refer to the Pregnancy  section of the protocol for appropriate 
immediately  reportable event reporting.
4.1.3 Extrapy ramidal Sy mptom Scales
The Abnormal Involuntary  Movement Scale (AIMS) and Barnes Akathisia Rating Scale
(BARS) will be assessed at the virtual visits defined in this COVI D-19 Addendum 
Schedule sof Assessments ( Table 1.2-1 and Table 1.2-2)by [CONTACT_826381]. The Simpson 
Angus Scale (SAS) will not be assessed remotely.Clinical Study Report 331-201-[ADDRESS_1146252] will be shipped directly to caregivers and subjects as 
per existing procedures for this trial.
6 Prohibited Medications (Delayed Rollover Subjects From 
Trial 331-201-[ZIP_CODE])
Delayed rollover subjects must agree to discontinue all prohibited medications during the 
screening period, after signing the informed consent form/informed assent form, in order 
to meet the protocol-specified washout periods. Table 6-[ADDRESS_1146253] dose of IMP.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
Table6-1CCI
CCI
Protocol [ADDRESS_1146254] of Washout of Prohibited Medications for Delayed 
Rollover Subjects From Trial 331-201-[ZIP_CODE]
Medication Required Washout Prior to 
Dosing
Antipsychotics
Oral aripi[INVESTIGATOR_826351] (other than cariprazine and clozapi[INVESTIGATOR_050]) 
Depot or long -acting injectable antipsychotics or clozapi[INVESTIGATOR_050]14 days
7 days
EXCLUDED
Antidepressants
Fluoxetine or Symby[CONTACT_826382] e and desvenlafaxine
All other antidepressants28 days
14 days
14 days
14 days
14 days
Other psychotropi[INVESTIGATOR_826352] w ithout ADHD 
diagnosis -7 days 
Stimulants Minimum 5Ã— half -life for subjects 
without diagnosis of ADHD 
Mood stabilizers (ie, lithium or anticonvulsants) 7 days
Varenicline 5 days
Oral benzodiazepi[INVESTIGATOR_826353], oxazepam, diazepam, or clonazepam
Other benzodiazepi[INVESTIGATOR_1651]8 hours before scalesb
14 days
CYP2D6 inhibitors and CYP3A4 inhibitors and inducers 
(seeTable 4.1-3 of the protocol ).14 days
ADHD = attention -deficit/hyperactivity disorder; CYP = cytochrome P450 .
aUse of intramuscular benzodiazepi[INVESTIGATOR_826335]. However, limited use of specific oral benzodiazepi[INVESTIGATOR_826354] 4.1-2of the protocol .
bBenzodiazepi[INVESTIGATOR_826355] w ithin [ADDRESS_1146255] ati o n of a n el e ctr o ni c all y c a pt ur e d si g n at ur e 
SI G N A T U R E P A G E 
D o c u m e nt N a m e: Pr ot o c ol 3 3 1- 2 0 1- 0 0 1 9 1 A d d e n d u m 
D o c u m e nt N u m b er: 
D o c u m e nt V er si o n: 2. 0 
Si g n e d b y M e a ni n g of Si g n at ur e S er v er D at e 
( d d- M M M- 
y y y y h h: mi n) - 
U T C ti m e z o n e 
Bi o st ati sti c s A p pr o v al 0 7- J ul- 2 0 2 0 
2 1: 1 5: 1 8 
A p pr o v e d f or Cli ni c al 
P h ar m a c ol o g y 
a n d N o n cli ni c al 0 7- J ul- 2 0 2 0 
1 6: 3 2: 0 8 
Cli ni c al A p pr o v al 0 7- J ul- 2 0 2 0 
1 5: 5 5: [ADDRESS_1146256] u d y Re p ort 3 3 1- 2 0 1- 0 0 1 9 1 1 6. 1. 1 Pr ot oc ol a n d Pr ot oc ol A me n d me nts 
U ntil t he i nf or m ati o n herei n is rele ase d b y Ots u k a t o t he p u blic d o m ai n, t he c o nte nts of t his d oc u me nt are Ots u k a 
c o nfi de nti al i nf or m ati o n a n d s h o ul d n ot be d u plic ate d or re- distri b ute d wit h o ut pri or writte n c o nse nt of Ots u k a. 
1 1 7 C CI 
P P D 
P P D 
P P D 